{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Oral berberine improves glycemic control in adults with type 2 diabetes.", "entry_form": "claim", "gradeable_restatement": "Oral berberine improves glycemic control in adults with type 2 diabetes.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Baseline diabetes, product, dose, comparator, background medication and follow-up specified before outcomes; no responder-defined beneficiaries", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ] }, "hypothesis": { "name": "Berberine and Glycemic Control", "central_claim": "Oral berberine improves glycemic control in adults with type 2 diabetes.", "proposed_mechanism": "Oral berberine improves glycemic control in adults with type 2 diabetes.", "claimed_scope": "Oral defined berberine exposure in adults with baseline type 2 diabetes, at least twelve weeks, credible controlled HbA1c and glucose comparisons with fixed background medication", "claimed_level": [ "response", "maintenance" ], "is_conjunctive": false, "conjunctive_note": "The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint." }, "rubric_routing": { "primary_rubric": "06-metabolism-aging.md", "secondary_rubrics": [], "index_notes_applied": [ "The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint." ], "rubric_fit_note": "The frozen framework has no clinical endocrine-treatment rubric. Rubric06 lifespan/healthspan criteria are quoted unchanged. An explicit clinical-phenotype adaptation treats HbA1c together with glucose measures as the registered glycemic-control phenotype, rather than requiring a lifespan experiment for a diabetes-treatment question. This is not a claim that HbA1c is a hard cardiovascular endpoint. Literal marker caps still govern downstream complication, functional, mortality, aging and mechanism-mediation inferences. Directly measured human clinical glycemia is not re-capped for studying only humans or for being measured in blood." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Berberine exposure engages candidate metabolic pathways.", "subclaim_type": "mechanism", "scope": "Product composition, dose and baseline diabetes measured", "claimed_scope": "Product composition, dose and baseline diabetes measured", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Human pharmacodynamic and relevant model perturbations", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Exposure and candidate pathway engagement are supported by human PK, the acute healthy-human KCNH6 clamp, PREMOTE microbial/metabolite analyses and causal perturbations in mice and cells. These demonstrate plausible multiple routes, but do not isolate a unique endogenous mechanism for chronic human T2D benefit. Model specificity and biomarker-to-human mediation inferences remain Γ; the actual drug treatment effect is scored separately.", "rubric_adaptation": "Candidate target engagement is distinct from human chronic mediation. Physiological channel dependence in mice and acute healthy-human insulin secretion cannot isolate the clinical T2D pathway; marker and system-transfer limits remain explicit." }, { "id": "SC2", "statement": "Oral berberine improves HbA1c and clinical glycemic control against a credible comparator.", "subclaim_type": "sufficiency", "scope": "Adults with baseline type 2 diabetes; at least 12 weeks; co-medication fixed", "claimed_scope": "Adults with baseline type 2 diabetes; at least 12 weeks; co-medication fixed", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Controlled clinical treatment comparisons", "hsef_level": "Δ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "PREMOTE provides a verified twelve-week, concealed, double-blind placebo comparison in drug-naive T2D adults with synthesized berberine 1.2g/day. HbA1c fell by0.99 versus0.59 percentage points; the incremental effect is approximately0.40 percentage points rather than the entire within-arm fall. The older 116-person placebo-controlled three-month trial also supports a glycemic effect. With the explicit clinical-phenotype adaptation, these positive randomized comparisons cross Δ for the registered glycemic-control phenotype. Durable treatment effects across the full range of baseline T2D, products and co-medication have not been mapped. Diabetes-free adiposity nulls do not manufacture an Ε boundary within the registered T2D scope.", "rubric_adaptation": "The field-valid clinical equivalent is randomized oral defined berberine versus a credible retained comparator in adults with baseline T2D for at least twelve weeks, with fixed background medication and positive HbA1c/glucose control. HbA1c is the preregistered treatment phenotype; cardiovascular events, quality of life, complications and longevity remain separate outcomes. Common gentamicin run-in is disclosed rather than treated as a hidden unbalanced confounder." }, { "id": "SC3", "statement": "Berberine is clinically equivalent to modern GLP-1 medicines for weight loss and cardiometabolic outcomes.", "subclaim_type": "generalization", "scope": "Direct molecule, exposure and outcome matched comparison", "claimed_scope": "Direct molecule, exposure and outcome matched comparison", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Noninferiority clinical trials", "hsef_level": "Α", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "No examined direct, matched, powered noninferiority comparison establishes berberine equivalence to modern GLP-1 medicines for weight loss or cardiometabolic outcomes. Metformin pilot similarity, short antipsychotic-weight studies and BUDCA biomarker effects are different interventions or contexts. The large six-month diabetes-free obesity trial was null for visceral and liver fat and body composition. Exact class-equivalence claims remain Α, without treating absence of a direct comparison as proof of inferiority on every outcome.", "rubric_adaptation": "Clinical equivalence requires direct molecule/exposure/outcome-matched noninferiority trials against modern GLP-1 medicines. An acute endogenous GLP-1 signal, metformin similarity or different-formulation HbA1c change is not such a trial." }, { "id": "SC4", "statement": "Berberine, glutathione and NMN combination stacks have established net clinical benefit.", "subclaim_type": "generalization", "scope": "Exact combination and functional or clinical outcome specified", "claimed_scope": "Exact combination and functional or clinical outcome specified", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Combination and component-dismantling trials", "hsef_level": "Α", "confidence": "Low", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "No examined trial tests the exact berberine, glutathione and NMN combination with clinical or functional net benefit and component-dismantling controls. Ingredient-specific NAD, glutathione and short functional findings are real but do not establish a triple-stack interaction or long-term safety. Exact stack-benefit claims remain Α; this does not negate separate ingredient effects.", "rubric_adaptation": "Exact triple-stack net clinical benefit requires the defined combination, clinical/function readouts, sufficient safety follow-up and component controls. Separate NMN, direct glutathione, GlyNAC and berberine-containing bundles cannot be summed into a combination result." } ], "aggregation_rule": "primary-subclaim", "aggregation_preregistered": true, "aggregation_rationale": "The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint.", "primary_subclaim_id": "SC2", "aggregation_derivation": "The preregistered primary-subclaim rule returns Δ from SC2: defined oral berberine has a positive controlled treatment effect on twelve-week T2D glycemic control. The claim is deliberately narrower than weight loss, GLP-1 equivalence, complication prevention or rejuvenation stacks. Sixty-three original reports include clinical efficacy, exposure and interaction studies, relevant model experiments and companion ingredients; they are not sixty-three isolated T2D efficacy trials. Weakest-link returns Α because the separate equivalence and exact-stack companions lack direct evidence; primary-subclaim and scope-matched return Δ. Repeated trials increase confidence but do not automatically become independently failing causal lines or identify a unique mediator.", "aggregation_alternatives": { "weakest_link_would_return": "Α", "primary_subclaim_would_return": "Δ", "scope_matched_would_return": "Δ", "note": "Separate narrow successes do not replace the preregistered full-scope gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M1", "is_nominal": true, "name": "Defined berberine has a glycemic treatment effect", "core_claim": "Oral berberine itself contributes to glycemic control in adults with T2D under tested conditions.", "explains_what_nominal_does_not": "Oral berberine itself contributes to glycemic control in adults with T2D under tested conditions.", "strongest_supporting_evidence": [ "Concealed placebo-controlled PREMOTE isolates ordinary berberine from probiotics and demonstrates incremental HbA1c benefit (PMID33024120); the older placebo trial supports three-month glycemic efficacy (PMID18397984)." ], "strongest_contradictory_evidence": [ "Common antibiotic pretreatment, short duration, product standardization and predominantly Chinese trial settings limit generalization. Unique mechanism and clinical complication benefit are not established." ], "hsef_level_for_this_model": "Δ", "rationale": "Concealed placebo-controlled PREMOTE isolates ordinary berberine from probiotics and demonstrates incremental HbA1c benefit (PMID33024120); the older placebo trial supports three-month glycemic efficacy (PMID18397984). Common antibiotic pretreatment, short duration, product standardization and predominantly Chinese trial settings limit generalization. Unique mechanism and clinical complication benefit are not established." }, { "rank_in_tournament": 2, "model_id": "M3", "is_nominal": false, "name": "Metabolic engagement is multiple and does not establish class equivalence", "core_claim": "Gut, receptor, mitochondrial and secretion pathways may contribute differently depending on exposure and biological context; engagement does not predict universal weight or clinical outcome effects.", "explains_what_nominal_does_not": "Gut, receptor, mitochondrial and secretion pathways may contribute differently depending on exposure and biological context; engagement does not predict universal weight or clinical outcome effects.", "strongest_supporting_evidence": [ "KCNH6 knockout and acute human clamp results (PMID34556670), SIRT3/model perturbations (PMID30117113), and a nontransferable microbiome result (PMID33994854) support multiple routes; the large obesity trial shows lipid markers can improve while adiposity and glycemia remain null (PMID41543854)." ], "strongest_contradictory_evidence": [ "No experiment isolates a unique chronic human T2D mediator. Opposite acute islet secretion effects (PMID29467344,18511510) challenge unconditional secretion accounts; genotype/system transfer retains Γ." ], "hsef_level_for_this_model": "Γ", "rationale": "KCNH6 knockout and acute human clamp results (PMID34556670), SIRT3/model perturbations (PMID30117113), and a nontransferable microbiome result (PMID33994854) support multiple routes; the large obesity trial shows lipid markers can improve while adiposity and glycemia remain null (PMID41543854). No experiment isolates a unique chronic human T2D mediator. Opposite acute islet secretion effects (PMID29467344,18511510) challenge unconditional secretion accounts; genotype/system transfer retains Γ." }, { "rank_in_tournament": 3, "model_id": "M2", "is_nominal": false, "name": "Comparator, co-medication and product context inflate broad claims", "core_claim": "Some apparent treatment magnitudes or broad cardiometabolic benefits reflect background improvement, bundles, product differences and active-comparator interpretation.", "explains_what_nominal_does_not": "Some apparent treatment magnitudes or broad cardiometabolic benefits reflect background improvement, bundles, product differences and active-comparator interpretation.", "strongest_supporting_evidence": [ "PREMOTE placebo HbA1c fell0.59 percentage points; berberine/cinnamon and multinutraceutical trials change more than one ingredient (PMID39998703,34371883), and metformin comparison is a small pilot (PMID18442638)." ], "strongest_contradictory_evidence": [ "This cannot explain away PREMOTE's randomized incremental ordinary-berberine effect. It is a source-specific explanation of overextended effect sizes rather than evidence that all efficacy is confounded." ], "hsef_level_for_this_model": "Γ", "rationale": "PREMOTE placebo HbA1c fell0.59 percentage points; berberine/cinnamon and multinutraceutical trials change more than one ingredient (PMID39998703,34371883), and metformin comparison is a small pilot (PMID18442638). This cannot explain away PREMOTE's randomized incremental ordinary-berberine effect. It is a source-specific explanation of overextended effect sizes rather than evidence that all efficacy is confounded." }, { "rank_in_tournament": 4, "model_id": "M4", "is_nominal": false, "name": "Exact stack synergy improves clinical outcomes", "core_claim": "A defined combination of berberine, glutathione and NMN produces net clinical benefit beyond its individual ingredients.", "explains_what_nominal_does_not": "A defined combination of berberine, glutathione and NMN produces net clinical benefit beyond its individual ingredients.", "strongest_supporting_evidence": [ "Separate oral glutathione target engagement (PMID24791752), NMN muscle insulin sensitivity (PMID33888596), and GlyNAC functional signals (PMID35975308) provide ingredient-level motivation." ], "strongest_contradictory_evidence": [ "None tests the exact triple stack; GlyNAC is a precursor combination, and some NMN primary/functional outcomes are null (PMID38789831,36740954). Ingredient plausibility cannot establish combination synergy or chronic net safety." ], "hsef_level_for_this_model": "Α", "rationale": "Separate oral glutathione target engagement (PMID24791752), NMN muscle insulin sensitivity (PMID33888596), and GlyNAC functional signals (PMID35975308) provide ingredient-level motivation. None tests the exact triple stack; GlyNAC is a precursor combination, and some NMN primary/functional outcomes are null (PMID38789831,36740954). Ingredient plausibility cannot establish combination synergy or chronic net safety." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. PREMOTE's ordinary-berberine versus matching-placebo contrast (PMID33024120), under the same antibiotic/lifestyle background, separates a real incremental glycemic treatment effect from a model in which every apparent improvement is explained by cointerventions. It does not identify the uniquely necessary human mediator or demonstrate GLP-1 equivalence.", "study_separating_rank1_from_rank2": "PREMOTE's ordinary-berberine versus matching-placebo contrast (PMID33024120), under the same antibiotic/lifestyle background, separates a real incremental glycemic treatment effect from a model in which every apparent improvement is explained by cointerventions. It does not identify the uniquely necessary human mediator or demonstrate GLP-1 equivalence.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "33024120", "title": "Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).", "citation": "Zhang Y, Gu Y, Ren H et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nature communications. 2020.", "doi": "10.1038/s41467-020-18414-8", "pmcid": "PMC7538905", "url": "https://pubmed.ncbi.nlm.nih.gov/33024120/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33024120/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PREMOTE_NCT02861261", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph9, 1:Results:paragraph17, 1:Results:paragraph18, 3:Methods:paragraph0, 3:Methods:paragraph1, 3:Methods:paragraph2, 3:Methods:paragraph55, 3:Methods:paragraph56, 3:Methods:paragraph76. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [ "M1", "M3" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "PREMOTE randomized drug-naive newly diagnosed T2D patients to synthesized berberine 1.2g daily or matched placebo for12weeks after common gentamicin pretreatment; original Methods verify concealed age-stratified allocation and blinding. HbA1c reduction -0.99 vs-0.59 percentage points; more GI adverse events. Original Results391/409 primary-analysis participants; probiotic addition did not improve HbA1c.", "what_it_does_not_show": "Observed treatment effect is conditional on this antibiotic/lifestyle background and duration; microbial covariance does not prove unique human mediation or long-term complication benefit.", "confounders_present": [ "Observed treatment effect is conditional on this antibiotic/lifestyle background and duration; microbial covariance does not prove unique human mediation or long-term complication benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 2, "pmid": "40029660", "title": "Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial.", "citation": "Ji L, Ma J, Ma Y et al. Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial. JAMA network open. 2025.", "doi": "10.1001/jamanetworkopen.2024.62185", "pmcid": "PMC11877176", "url": "https://pubmed.ncbi.nlm.nih.gov/40029660/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40029660/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "HTD1801_T2D_12week_phaseII", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph3, 1:Methods:paragraph4, 2:Results:paragraph0, 2:Results:paragraph5, 2:Results:paragraph18, 2:Results:paragraph20. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Distinct HTD1801 berberine-ursodeoxycholate formulation113 randomized T2D patients for12weeks; original Methods/Results confirm matched placebo and placebo-adjusted HbA1c -0.4/-0.7 percentage points by dose; weight remained stable.", "what_it_does_not_show": "BUDCA is a new combined molecular entity; benefit cannot be assigned to ordinary berberine alone or borrowed for GLP1 weight-loss equivalence. No cardiovascular event endpoint.", "confounders_present": [ "BUDCA is a new combined molecular entity; benefit cannot be assigned to ordinary berberine alone or borrowed for GLP1 weight-loss equivalence. No cardiovascular event endpoint." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 3, "pmid": "18397984", "title": "Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.", "citation": "Zhang Y, Li X, Zou D et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. The Journal of clinical endocrinology and metabolism. 2008.", "doi": "10.1210/jc.2007-2404", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/18397984/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18397984/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Zhang_T2D_dyslipidemia_2008", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "116 T2D/dyslipidemia patients randomly allocated berberine1g daily or placebo for3months; HbA1c7.5 to6.6 and fasting/postload glucose improvements differed significantly from placebo; constipation in5.", "what_it_does_not_show": "Within-arm change is not the treatment difference; clamp disposal change did not differ significantly between arms P=.063. Abstract-level access does not verify every allocation/adherence detail or hard outcomes.", "confounders_present": [ "Within-arm change is not the treatment difference; clamp disposal change did not differ significantly between arms P=.063. Abstract-level access does not verify every allocation/adherence detail or hard outcomes." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 4, "pmid": "37679692", "title": "Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial.", "citation": "Panigrahi A, Mohanty S. Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. BMC endocrine disorders. 2023.", "doi": "10.1186/s12902-023-01442-y", "pmcid": "PMC10483788", "url": "https://pubmed.ncbi.nlm.nih.gov/37679692/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37679692/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37679692", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "34 prediabetic participants in12week double-blind pilot; branded berberine1.5g daily improved HbA1c and fasting/OGTT markers versus placebo.", "what_it_does_not_show": "Baseline prediabetes is outside registered T2D scope; small pilot does not establish prevention of diabetes, GLP1 equivalence, or durable clinical outcomes.", "confounders_present": [ "Baseline prediabetes is outside registered T2D scope; small pilot does not establish prevention of diabetes, GLP1 equivalence, or durable clinical outcomes." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 5, "pmid": "34535644", "title": "A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes.", "citation": "Harrison SA, Gunn N, Neff GW et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature communications. 2021.", "doi": "10.1038/s41467-021-25701-5", "pmcid": "PMC8448729", "url": "https://pubmed.ncbi.nlm.nih.gov/34535644/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34535644/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "HTD1801_NCT03656744", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "100 presumed NASH plus T2D participants randomized18weeks to BUDCA versus placebo; high-dose liver fat -4.8 vs-2.0%, glycemic and weight improvements reported.", "what_it_does_not_show": "UDCA-containing ionic salt differs from pure berberine; liver-fat imaging and secondary glycemia do not establish biopsy resolution or class equivalence.", "confounders_present": [ "UDCA-containing ionic salt differs from pure berberine; liver-fat imaging and secondary glycemia do not establish biopsy resolution or class equivalence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 6, "pmid": "39998703", "title": "The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial.", "citation": "Mansour A, Sajjadi-Jazi SM, Gerami H et al. The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial. European journal of nutrition. 2025.", "doi": "10.1007/s00394-025-03618-9", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39998703/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39998703/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39998703", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [ "M2" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "12week double-blind T2D trial of berberine1.2g plus cinnamon600mg daily versus placebo reported lower fasting glucose and HbA1c but no anthropometric difference.", "what_it_does_not_show": "No berberine-only or cinnamon-only dismantling arms; bundle effect cannot isolate berberine or validate the glutathione/NMN stack.", "confounders_present": [ "No berberine-only or cinnamon-only dismantling arms; bundle effect cannot isolate berberine or validate the glutathione/NMN stack." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 7, "pmid": "35999562", "title": "The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial.", "citation": "Nematollahi S, Pishdad GR, Zakerkish M et al. The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial. Diabetology & metabolic syndrome. 2022.", "doi": "10.1186/s13098-022-00888-9", "pmcid": "PMC9395822", "url": "https://pubmed.ncbi.nlm.nih.gov/35999562/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35999562/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35999562", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "50 randomized T2D patients received900mg berberine plus600mg fenugreek daily or placebo for12weeks; fasting-glucose/insulin between-arm signals and SF12 gains; HbA1c improvement reported within arm.", "what_it_does_not_show": "Within-arm HbA1c is insufficient evidence of between-arm efficacy; no single-component arms or exact triple stack; small trial and many endpoints.", "confounders_present": [ "Within-arm HbA1c is insufficient evidence of between-arm efficacy; no single-component arms or exact triple stack; small trial and many endpoints." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 8, "pmid": "24250489", "title": "The Effects of Berberis vulgaris Fruit Extract on Serum Lipoproteins, apoB, apoA-I, Homocysteine, Glycemic Control and Total Antioxidant Capacity in Type 2 Diabetic Patients.", "citation": "Shidfar F, Ebrahimi SS, Hosseini S et al. The Effects of Berberis vulgaris Fruit Extract on Serum Lipoproteins, apoB, apoA-I, Homocysteine, Glycemic Control and Total Antioxidant Capacity in Type 2 Diabetic Patients. Iranian journal of pharmaceutical research : IJPR. 2012.", "doi": "", "pmcid": "PMC3832145", "url": "https://pubmed.ncbi.nlm.nih.gov/24250489/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24250489/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24250489", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "31 T2D participants randomized3months to Berberis fruit extract3g daily or placebo; glucose/insulin and lipid effects positive while HbA1c showed no significant between-arm change.", "what_it_does_not_show": "Fruit extract is multicomponent and dose not equivalent to isolated berberine; this null HbA1c does not falsify the pure-drug exposure hypothesis.", "confounders_present": [ "Fruit extract is multicomponent and dose not equivalent to isolated berberine; this null HbA1c does not falsify the pure-drug exposure hypothesis." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 9, "pmid": "18442638", "title": "Efficacy of berberine in patients with type 2 diabetes mellitus.", "citation": "Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental. 2008.", "doi": "10.1016/j.metabol.2008.01.013", "pmcid": "PMC2410097", "url": "https://pubmed.ncbi.nlm.nih.gov/18442638/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18442638/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18442638", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "StudyA36 newly diagnosed T2D adults randomized berberine versus metformin for3months with similar glycemic reductions; StudyB48 poorly controlled adults added berberine and HbA1c fell; GI effects34.5% across reported patients.", "what_it_does_not_show": "Active-comparator pilot was not a powered noninferiority demonstration; uncontrolled add-on StudyB cannot isolate treatment effect. Metformin similarity is not modern GLP1 equivalence.", "confounders_present": [ "Active-comparator pilot was not a powered noninferiority demonstration; uncontrolled add-on StudyB cannot isolate treatment effect. Metformin similarity is not modern GLP1 equivalence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 10, "pmid": "39943692", "title": "The Pharmacokinetic Interaction Between Metformin and the Natural Product Goldenseal Is Metformin Dose-Dependent: A Three-Arm Crossover Study in Adults With Type 2 Diabetes.", "citation": "Nguyen JT, Arian CM, Tanna RS et al. The Pharmacokinetic Interaction Between Metformin and the Natural Product Goldenseal Is Metformin Dose-Dependent: A Three-Arm Crossover Study in Adults With Type 2 Diabetes. Clinical and translational science. 2025.", "doi": "10.1111/cts.70120", "pmcid": "PMC11821731", "url": "https://pubmed.ncbi.nlm.nih.gov/39943692/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39943692/", "tier": "A", "source_tier": "A", "kind": "human_pharmacokinetic_crossover", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39943692", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "T2D three-arm crossover goldenseal/metformin interaction study showed aggregate metforminAUC ratio.93 within no-effect band, but dose-dependent reductions around20% at lower metformin dose; HbA1c exploratory reduction.", "what_it_does_not_show": "Goldenseal contains multiple alkaloids; brief PK does not establish pure-berberine12week efficacy or the absence of clinically important individual interactions.", "confounders_present": [ "Goldenseal contains multiple alkaloids; brief PK does not establish pure-berberine12week efficacy or the absence of clinically important individual interactions." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 11, "pmid": "23869585", "title": "The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment.", "citation": "An Y, Sun Z, Zhang Y et al. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical endocrinology. 2014.", "doi": "10.1111/cen.12294", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/23869585/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23869585/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23869585", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "150 PCOS infertility patients randomized berberine/metformin/placebo beforeIVF; metabolic and pregnancy outcomes improved, with more live births than metformin reported.", "what_it_does_not_show": "PCOS/IVF population and reproductive endpoints are outside T2D scope; no GLP1 comparator, weight-loss equivalence, or general pregnancy-safety demonstration.", "confounders_present": [ "PCOS/IVF population and reproductive endpoints are outside T2D scope; no GLP1 comparator, weight-loss equivalence, or general pregnancy-safety demonstration." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 12, "pmid": "19800084", "title": "Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.", "citation": "Zhang H, Wei J, Xue R et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism: clinical and experimental. 2010.", "doi": "10.1016/j.metabol.2009.07.029", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19800084/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19800084/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19800084", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Human cell lines showed increased insulin-receptor expression and clinical T2D treatment HbA1c/fasting glucose reductions similar to metformin/rosiglitazone; peripheral lymphocyte receptor signal increased.", "what_it_does_not_show": "Abstract does not report clinical duration or sufficient comparator/control detail for registered threshold credit; lymphocyte marker correlation does not isolate causal receptor mediation.", "confounders_present": [ "Abstract does not report clinical duration or sufficient comparator/control detail for registered threshold credit; lymphocyte marker correlation does not isolate causal receptor mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 13, "pmid": "42249406", "title": "Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial.", "citation": "Mai J, Zhang H, Wu M et al. Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial. Diabetology & metabolic syndrome. 2026.", "doi": "10.1186/s13098-026-02202-3", "pmcid": "PMC13459767", "url": "https://pubmed.ncbi.nlm.nih.gov/42249406/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42249406/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "HTD1801_28day_phaseIb", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "PhaseIb48 T2D/MASLD patients included treatment-naive cohorts and12 on stable metformin;28day HTD1801 exposure improved fasting/postprandial measures with tolerable short-term events.", "what_it_does_not_show": "Only28days and distinct BUDCA formulation; retrospectively registered. Does not meet12week pure-berberine SC2 or demonstrate chronic safety.", "confounders_present": [ "Only28days and distinct BUDCA formulation; retrospectively registered. Does not meet12week pure-berberine SC2 or demonstrate chronic safety." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 14, "pmid": "34371883", "title": "Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial.", "citation": "Sartore G, Ragazzi E, Antonello G et al. Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial. Nutrients. 2021.", "doi": "10.3390/nu13072373", "pmcid": "PMC8308828", "url": "https://pubmed.ncbi.nlm.nih.gov/34371883/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34371883/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34371883", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "12week randomized add-on formulation berberine/hesperidin/chromium plus metformin improved HbA1c and fasting glucose versus metformin-only control.", "what_it_does_not_show": "No ingredient dismantling, placebo masking not established in abstract, and composition differs from exact glutathione/NMN stack; relative HbA1c change not percentage-point effect.", "confounders_present": [ "No ingredient dismantling, placebo masking not established in abstract, and composition differs from exact glutathione/NMN stack; relative HbA1c change not percentage-point effect." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 15, "pmid": "22019891", "title": "A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome.", "citation": "Wei W, Zhao H, Wang A et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European journal of endocrinology. 2012.", "doi": "10.1530/EJE-11-0616", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/22019891/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22019891/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID22019891", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "89 PCOS/IR women randomized berberine/metformin/placebo with common cyproterone for3months; metabolic and hormonal effects versus placebo.", "what_it_does_not_show": "PCOS and common hormonal treatment differ from baseline T2D; metabolic marker effects do not establish GLP1 equivalence or cardiovascular benefit.", "confounders_present": [ "PCOS and common hormonal treatment differ from baseline T2D; metabolic marker effects do not establish GLP1 equivalence or cardiovascular benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 16, "pmid": "34773803", "title": "Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin.", "citation": "Qiu Y, Li M, Zhang Y et al. Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin. Asian journal of psychiatry. 2022.", "doi": "10.1016/j.ajp.2021.102896", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/34773803/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34773803/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34773803", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "65 schizophrenia patients on stable antipsychotic randomized8weeks;49 completed; berberine weight -1.10kg versus placebo+1.45kg, with leptin covariation.", "what_it_does_not_show": "Attrition and distinct drug-induced weight-gain context; no baseline T2D requirement,12week observation, GLP1 head-to-head, or proof leptin mediates effect.", "confounders_present": [ "Attrition and distinct drug-induced weight-gain context; no baseline T2D requirement,12week observation, GLP1 head-to-head, or proof leptin mediates effect." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 17, "pmid": "28800398", "title": "A 13-week low glycemic load diet and lifestyle modification program combining low glycemic load protein shakes and targeted nutraceuticals improved weight loss and cardio-metabolic risk factors.", "citation": "Dahlberg CJ, Ou JJ, Babish JG et al. A 13-week low glycemic load diet and lifestyle modification program combining low glycemic load protein shakes and targeted nutraceuticals improved weight loss and cardio-metabolic risk factors. Canadian journal of physiology and pharmacology. 2017.", "doi": "10.1139/cjpp-2016-0704", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/28800398/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28800398/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28800398", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M2" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "44 overweight adults randomized open-label diet versus multinutraceutical/protein-shake program13weeks; greater risk-factor/weight changes in bundle;12 discontinued beforeweek9.", "what_it_does_not_show": "Diet and many ingredients changed together; authors cannot separate supplement from synergy. Predicted Framingham risk is not observed event reduction and exact triple stack untested.", "confounders_present": [ "Diet and many ingredients changed together; authors cannot separate supplement from synergy. Predicted Framingham risk is not observed event reduction and exact triple stack untested." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 18, "pmid": "25623616", "title": "An ex vivo approach to botanical-drug interactions: a proof of concept study.", "citation": "Wang X, Zhu HJ, Munoz J et al. An ex vivo approach to botanical-drug interactions: a proof of concept study. Journal of ethnopharmacology. 2015.", "doi": "10.1016/j.jep.2015.01.021", "pmcid": "PMC4355093", "url": "https://pubmed.ncbi.nlm.nih.gov/25623616/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25623616/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25623616", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "ex vivo", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Post-botanical human plasma incubation predicted CYP inhibition better than artificial buffers and mirrored goldenseal clinical interactions.", "what_it_does_not_show": "Method-development and multialkaloid exposures do not establish pure-berberine clinical net benefit; ex vivo assay is not a long-term stack safety trial.", "confounders_present": [ "Method-development and multialkaloid exposures do not establish pure-berberine clinical net benefit; ex vivo assay is not a long-term stack safety trial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 19, "pmid": "35785560", "title": "Biodistribution and pharmacokinetic profile of berberine and its metabolites in hepatocytes.", "citation": "Liu X, Li W, Zhang H et al. Biodistribution and pharmacokinetic profile of berberine and its metabolites in hepatocytes. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2022.", "doi": "10.1016/j.phymed.2022.154288", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/35785560/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35785560/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35785560", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "HepG2 LCMS identified phaseI/II berberine metabolites and intracellular enrichment of demethyleneberberine.", "what_it_does_not_show": "Transformed cells and metabolite distribution cannot establish systemic target exposure, mechanism necessity, or clinical T2D glycemic efficacy.", "confounders_present": [ "Transformed cells and metabolite distribution cannot establish systemic target exposure, mechanism necessity, or clinical T2D glycemic efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 20, "pmid": "16541194", "title": "The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers.", "citation": "Xin HW, Wu XC, Li Q et al. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods and findings in experimental and clinical pharmacology. 2006.", "doi": "10.1358/mf.2006.28.1.962774", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/16541194/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16541194/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16541194", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Two small healthy-male PK groups found no significant CsA change at6mg/kg but19.2% AUC increase at3mg/kg with berberine.", "what_it_does_not_show": "Dose-specific interaction signal and proposed CYP/gastric mechanisms not isolated; does not quantify clinical transplant harms or safety of exact stack.", "confounders_present": [ "Dose-specific interaction signal and proposed CYP/gastric mechanisms not isolated; does not quantify clinical transplant harms or safety of exact stack." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 21, "pmid": "26268432", "title": "Pharmacokinetics of a multicomponent herbal preparation in healthy Chinese and African volunteers.", "citation": "Alolga RN, Fan Y, Zhang G et al. Pharmacokinetics of a multicomponent herbal preparation in healthy Chinese and African volunteers. Scientific reports. 2015.", "doi": "10.1038/srep12961", "pmcid": "PMC4534804", "url": "https://pubmed.ncbi.nlm.nih.gov/26268432/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26268432/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID26268432", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Six healthy volunteers took multicomponent K601; berberine and other absorbed alkaloid PK measured, with apparent population differences.", "what_it_does_not_show": "Tiny multicomponent influenza-preparation exposure study; no T2D outcome, no pure-drug pharmacodynamic mediation, and no population-wide ethnic PK inference.", "confounders_present": [ "Tiny multicomponent influenza-preparation exposure study; no T2D outcome, no pure-drug pharmacodynamic mediation, and no population-wide ethnic PK inference." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 22, "pmid": "21870106", "title": "Repeated administration of berberine inhibits cytochromes P450 in humans.", "citation": "Guo Y, Chen Y, Tan ZR et al. Repeated administration of berberine inhibits cytochromes P450 in humans. European journal of clinical pharmacology. 2012.", "doi": "10.1007/s00228-011-1108-2", "pmcid": "PMC4898966", "url": "https://pubmed.ncbi.nlm.nih.gov/21870106/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21870106/", "tier": "A", "source_tier": "A", "kind": "human_pharmacokinetic_crossover", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID21870106", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Randomized crossover repeated900mg/day berberine2weeks in healthy men decreased CYP2D6/2C9/3A4 activity; midazolamAUC about40% higher.", "what_it_does_not_show": "Healthy-probe PK and short duration do not establish all-drug interactions or net long-term stack benefit; legitimate interaction evidence narrows simple safety narratives.", "confounders_present": [ "Healthy-probe PK and short duration do not establish all-drug interactions or net long-term stack benefit; legitimate interaction evidence narrows simple safety narratives." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 23, "pmid": "21319959", "title": "Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein.", "citation": "Zhang X, Qiu F, Jiang J et al. Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein. Xenobiotica; the fate of foreign compounds in biological systems. 2011.", "doi": "10.3109/00498254.2010.529180", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/21319959/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21319959/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID21319959", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Caco2 transport experiments with Pgp/MRP inhibitors identify berberine as Pgp substrate and increased absorptive transport with inhibitors.", "what_it_does_not_show": "Cell transport does not measure clinical bioavailability or disease phenotype; apparent paper-unit formatting retained rather than silently corrected.", "confounders_present": [ "Cell transport does not measure clinical bioavailability or disease phenotype; apparent paper-unit formatting retained rather than silently corrected." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 24, "pmid": "28744326", "title": "Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine.", "citation": "Wang Y, Tong Q, Shou JW et al. Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine. Theranostics. 2017.", "doi": "10.7150/thno.18290", "pmcid": "PMC5525748", "url": "https://pubmed.ncbi.nlm.nih.gov/28744326/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28744326/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28744326", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "High-fat-fed hamsters showed higher gut nitroreductase, berberine absorption and lipid response; human hyperlipidemia PK correlated with fecal enzyme activity.", "what_it_does_not_show": "Human correlation and hamster metabolic response do not establish human T2D microbial necessity; normal-diet lipid null is context specific, not a chronic glycemic boundary.", "confounders_present": [ "Human correlation and hamster metabolic response do not establish human T2D microbial necessity; normal-diet lipid null is context specific, not a chronic glycemic boundary." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 25, "pmid": "35975308", "title": "Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial.", "citation": "Kumar P, Liu C, Suliburk J et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. The journals of gerontology. Series A, Biological sciences and medical sciences. 2023.", "doi": "10.1093/gerona/glac135", "pmcid": "PMC9879756", "url": "https://pubmed.ncbi.nlm.nih.gov/35975308/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35975308/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35975308", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "24 older adults randomized16weeks GlyNAC versus alanine, with functional and molecular improvements; young comparison received2weeks.", "what_it_does_not_show": "Glycine/NAC precursors are not direct glutathione and no berberine/NMN combination; small multi-endpoint experiment does not validate exact stack or lifespan extension.", "confounders_present": [ "Glycine/NAC precursors are not direct glutathione and no berberine/NMN combination; small multi-endpoint experiment does not validate exact stack or lifespan extension." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 26, "pmid": "36482258", "title": "The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.", "citation": "Yi L, Maier AB, Tao R et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023.", "doi": "10.1007/s11357-022-00705-1", "pmcid": "PMC9735188", "url": "https://pubmed.ncbi.nlm.nih.gov/36482258/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36482258/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36482258", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "80 healthy middle-aged participants randomized60days NMN dose groups/placebo; NAD and6minute-walk gains, HOMAIR no significant difference; per-protocol analysis.", "what_it_does_not_show": "Ingredient-specific short-term outcomes and biological-age algorithm do not establish exact-stack benefit, diabetes treatment, or aging reversal.", "confounders_present": [ "Ingredient-specific short-term outcomes and biological-age algorithm do not establish exact-stack benefit, diabetes treatment, or aging reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 27, "pmid": "33888596", "title": "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.", "citation": "Yoshino M, Yoshino J, Kayser BD et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science (New York, N.Y.). 2021.", "doi": "10.1126/science.abe9985", "pmcid": "PMC8550608", "url": "https://pubmed.ncbi.nlm.nih.gov/33888596/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33888596/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33888596", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "10week double-blind NMN trial in overweight/obese postmenopausal prediabetic women improved clamp muscle glucose disposal and insulin signaling.", "what_it_does_not_show": "No T2D berberine arm or triple stack; local muscle insulin sensitivity does not establish systemic clinical glycemic outcomes or mortality benefit.", "confounders_present": [ "No T2D berberine arm or triple stack; local muscle insulin sensitivity does not establish systemic clinical glycemic outcomes or mortality benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 28, "pmid": "34238308", "title": "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study.", "citation": "Liao B, Zhao Y, Wang D et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Journal of the International Society of Sports Nutrition. 2021.", "doi": "10.1186/s12970-021-00442-4", "pmcid": "PMC8265078", "url": "https://pubmed.ncbi.nlm.nih.gov/34238308/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34238308/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34238308", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "48 amateur runners randomized NMN dose groups plus common training6weeks; ventilatory-threshold measures improved, VO2max and peak power did not.", "what_it_does_not_show": "Small sports cohort and selective physiological outcomes; no exact stack, disease outcomes, or general aging benefit.", "confounders_present": [ "Small sports cohort and selective physiological outcomes; no exact stack, disease outcomes, or general aging benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 29, "pmid": "35215405", "title": "Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study.", "citation": "Kim M, Seol J, Sato T et al. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients. 2022.", "doi": "10.3390/nu14040755", "pmcid": "PMC8877443", "url": "https://pubmed.ncbi.nlm.nih.gov/35215405/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35215405/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35215405", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "108 older adults randomized timing-specific NMN/placebo12weeks; sit-to-stand improved in allgroups and afternoon drowsiness improved with NMN and placebo; interactions reported.", "what_it_does_not_show": "Largest within-arm effect does not show universal NMN superiority; multiple groups/endpoints and no exact stack or glycemic disease scope.", "confounders_present": [ "Largest within-arm effect does not show universal NMN superiority; multiple groups/endpoints and no exact stack or glycemic disease scope." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 30, "pmid": "38789831", "title": "Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study.", "citation": "Morifuji M, Higashi S, Ebihara S et al. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience. 2024.", "doi": "10.1007/s11357-024-01204-1", "pmcid": "PMC11336149", "url": "https://pubmed.ncbi.nlm.nih.gov/38789831/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38789831/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38789831", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "60 older adults randomized NMN250mg/placebo12weeks; primary stepping test null, secondary walking-time/NAD/sleep signals positive.", "what_it_does_not_show": "Primary null must accompany secondary positives; ingredient trial cannot establish triple-stack net benefit or extended healthy life expectancy.", "confounders_present": [ "Primary null must accompany secondary positives; ingredient trial cannot establish triple-stack net benefit or extended healthy life expectancy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 31, "pmid": "31685720", "title": "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.", "citation": "Irie J, Inagaki E, Fujita M et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine journal. 2020.", "doi": "10.1507/endocrj.EJ19-0313", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31685720/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31685720/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID31685720", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Ten healthy men single-arm acute oralNMN100/250/500mg with metabolites and5hour laboratory measures; no major immediate abnormalities.", "what_it_does_not_show": "No randomized comparator or repeated exposure; absence of acute symptoms does not establish long-term safety, clinical efficacy, or stack benefit.", "confounders_present": [ "No randomized comparator or repeated exposure; absence of acute symptoms does not establish long-term safety, clinical efficacy, or stack benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 32, "pmid": "35182418", "title": "MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults.", "citation": "Pencina KM, Lavu S, Dos Santos M et al. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. The journals of gerontology. Series A, Biological sciences and medical sciences. 2023.", "doi": "10.1093/gerona/glac049", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/35182418/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35182418/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MIB626_14day_PK", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "32 older overweight/obese adults randomized pharmaceutical NMN14days; substantial dose-related NAD rise with short-term tolerability.", "what_it_does_not_show": "Biochemical exposure foundation only; no exact stack, durability, or functional disease benefit and no aging-causation proof.", "confounders_present": [ "Biochemical exposure foundation only; no exact stack, durability, or functional disease benefit and no aging-causation proof." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 33, "pmid": "33994854", "title": "Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver.", "citation": "Yu M, Alimujiang M, Hu L et al. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. International journal of biological sciences. 2021.", "doi": "10.7150/ijbs.54604", "pmcid": "PMC8120465", "url": "https://pubmed.ncbi.nlm.nih.gov/33994854/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33994854/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33994854", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M3" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Mouse berberine improved adiposity/IR while inhibiting gut/liver complexI; fecal transplantation failed to transfer metabolic effect, favoring nonmicrobial explanation in this model.", "what_it_does_not_show": "Mouse doses and tissue metabolism do not establish chronic human mediation; transplant negative contradicts obligatory transferable microbiome model, not all microbiome roles.", "confounders_present": [ "Mouse doses and tissue metabolism do not establish chronic human mediation; transplant negative contradicts obligatory transferable microbiome model, not all microbiome roles." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 34, "pmid": "34556670", "title": "Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.", "citation": "Zhao MM, Lu J, Li S et al. Berberine is an insulin secretagogue targeting the KCNH6 potassium channel. Nature communications. 2021.", "doi": "10.1038/s41467-021-25952-2", "pmcid": "PMC8460738", "url": "https://pubmed.ncbi.nlm.nih.gov/34556670/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34556670/", "tier": "A", "source_tier": "A", "kind": "original_model_and_acute_human_trial", "status_flags": [ "ErratumIn: PMID34716337" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "KCNH6_models_and_NCT03972215", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph4, 1:Results:paragraph6, 1:Results:paragraph26, 3:Methods:paragraph1, 3:Methods:paragraph7, 3:Methods:paragraph17, 3:Methods:paragraph18, 3:Methods:paragraph21. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [ "M3" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Original M/R verify global and beta-cell Kcnh6 knockout abolished acute berberine glucose/insulin effect while tolbutamide remained active;15 healthy men single-dose crossover clamp showed second-phase secretion increase.", "what_it_does_not_show": "Animal560mg/kg acute drug dependence plus healthy clamp does not establish endogenous human12week T2D mediation or GLP1 equivalence. Attached34716337 corrects an author-name typo only.", "confounders_present": [ "Animal560mg/kg acute drug dependence plus healthy clamp does not establish endogenous human12week T2D mediation or GLP1 equivalence. Attached34716337 corrects an author-name typo only." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [ "Human single-dose clamp and global/beta-cell knockout components are reported within one paper; do not count every subexperiment as an independent clinical efficacy line." ] }, { "n": 35, "pmid": "32770172", "title": "Berberine improves intralipid-induced insulin resistance in murine.", "citation": "Dong ZH, Lin HY, Chen FL et al. Berberine improves intralipid-induced insulin resistance in murine. Acta pharmacologica Sinica. 2021.", "doi": "10.1038/s41401-020-0493-4", "pmcid": "PMC8115075", "url": "https://pubmed.ncbi.nlm.nih.gov/32770172/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32770172/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32770172", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Acute intralipid insulin resistance improved with berberine; CypD deletion attenuated disease and diminished additional treatment effect; muscle-specific evidence with cells.", "what_it_does_not_show": "Acute clamp model and knockout baseline alteration do not isolate all chronic T2D treatment mechanisms or human relevance.", "confounders_present": [ "Acute clamp model and knockout baseline alteration do not isolate all chronic T2D treatment mechanisms or human relevance." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 36, "pmid": "34923903", "title": "Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.", "citation": "Wang S, Ren H, Zhong H et al. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study. Gut microbes. 2022.", "doi": "10.1080/19490976.2021.2003176", "pmcid": "PMC8726654", "url": "https://pubmed.ncbi.nlm.nih.gov/34923903/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34923903/", "tier": "A", "source_tier": "A", "kind": "secondary_trial_report", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PREMOTE_NCT02861261", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "365 PREMOTE participants secondary meal-test lipid analysis; probiotic plus berberine improved postprandial lipids, with Bbreve/fadD laboratory support.", "what_it_does_not_show": "Same parent trial33024120 and different endpoint; not independent glycemic replication, and postprandial lipid synergy is not HbA1c synergy or clinical event reduction.", "confounders_present": [ "Same parent trial33024120 and different endpoint; not independent glycemic replication, and postprandial lipid synergy is not HbA1c synergy or clinical event reduction." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "Same PREMOTE participants; postprandial lipid secondary outcome, not a new glycemic trial." ] }, { "n": 37, "pmid": "29247651", "title": "Berberine-induced activation of AMPK increases hepatic FGF21 expression via NUR77.", "citation": "Zhou F, Bai M, Zhang Y et al. Berberine-induced activation of AMPK increases hepatic FGF21 expression via NUR77. Biochemical and biophysical research communications. 2018.", "doi": "10.1016/j.bbrc.2017.12.070", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29247651/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29247651/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29247651", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Weak", "system": "ex vivo", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Primary mouse hepatocytes showed AMPK/NUR77/FGF21 response; constitutively activeAMPK and compoundC supported pathway involvement.", "what_it_does_not_show": "Expression endpoint in isolated cells plus ectopic activation/inhibitor specificity cannot establish endogenous organismal or clinical phenotype dependency.", "confounders_present": [ "Expression endpoint in isolated cells plus ectopic activation/inhibitor specificity cannot establish endogenous organismal or clinical phenotype dependency." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 38, "pmid": "30422704", "title": "Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids.", "citation": "Yue SJ, Liu J, Wang AT et al. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. American journal of physiology. Endocrinology and metabolism. 2019.", "doi": "10.1152/ajpendo.00256.2018", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/30422704/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30422704/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30422704", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "High-fat-fed mouse metabolic benefit cooccurred with lower BCAAs and microbiome shifts; ex vivo catabolism and human BCAA/glycemia data included.", "what_it_does_not_show": "Covarying pathways and unspecified human treatment design do not show unique microbial/BCAA mediation or satisfy registered clinical trial duration/comparator.", "confounders_present": [ "Covarying pathways and unspecified human treatment design do not show unique microbial/BCAA mediation or satisfy registered clinical trial duration/comparator." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 39, "pmid": "32745766", "title": "Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle.", "citation": "Yao S, Yuan Y, Zhang H et al. Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle. Free radical biology & medicine. 2020.", "doi": "10.1016/j.freeradbiomed.2020.07.028", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/32745766/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32745766/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32745766", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Mouse/myocyte berberine reduced ectopic muscle lipid and altered mitochondrial function; AMPK/PGC1alpha RNAinterference/adenovirus supported pathway linkage.", "what_it_does_not_show": "Lipid/mitochondrial endpoints and experimental constructs do not prove human T2D treatment mechanism or longevity benefits.", "confounders_present": [ "Lipid/mitochondrial endpoints and experimental constructs do not prove human T2D treatment mechanism or longevity benefits." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 40, "pmid": "41543854", "title": "Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.", "citation": "Lei L, Wang B, Zhao L et al. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. JAMA network open. 2026.", "doi": "10.1001/jamanetworkopen.2025.54152", "pmcid": "PMC12811813", "url": "https://pubmed.ncbi.nlm.nih.gov/41543854/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41543854/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41543854", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph8, 2:Results:paragraph0, 2:Results:paragraph7, 2:Results:paragraph13. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M3", "M2" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "Original Methods/Results:337 diabetes-free obese MASLD participants randomized6months1g/day berberine or matching placebo after tolerance/adherence run-in; VAT,liver fat,bodycomposition and HbA1c effects null despite modest LDL/apoB/CRP reduction.", "what_it_does_not_show": "Excludes diabetes and selects tolerant adherers; does not refute T2D glycemic efficacy or establish all-comer safety. Strong boundary against broad adiposity and biomarker-to-weight extrapolation.", "confounders_present": [ "Excludes diabetes and selects tolerant adherers; does not refute T2D glycemic efficacy or establish all-comer safety. Strong boundary against broad adiposity and biomarker-to-weight extrapolation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 41, "pmid": "30117113", "title": "Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3.", "citation": "Zhang B, Pan Y, Xu L et al. Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3. Endocrine. 2018.", "doi": "10.1007/s12020-018-1689-y", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/30117113/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30117113/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30117113", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Sirt3 knockout/overexpression and metabolic assays supported berberine-related mitochondrial/AMP/cAMP/glucose mechanisms and glucagon-pathway inhibition.", "what_it_does_not_show": "Multiple downstream routes and model intervention do not isolate human chronic mediation; mitochondrial inhibition is not automatically clinical mitochondrial injury.", "confounders_present": [ "Multiple downstream routes and model intervention do not isolate human chronic mediation; mitochondrial inhibition is not automatically clinical mitochondrial injury." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 42, "pmid": "25423280", "title": "Berberine activates thermogenesis in white and brown adipose tissue.", "citation": "Zhang Z, Zhang H, Li B et al. Berberine activates thermogenesis in white and brown adipose tissue. Nature communications. 2014.", "doi": "10.1038/ncomms6493", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/25423280/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25423280/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25423280", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Obese db/db mice berberine increased energy expenditure/BAT and limited weightgain; hypothalamicAMPK genetic activation did not prevent effect.", "what_it_does_not_show": "Obesity model thermogenesis does not establish adult clinical weightloss equivalence to GLP1 medicines or necessity of every proposedAMPK site.", "confounders_present": [ "Obesity model thermogenesis does not establish adult clinical weightloss equivalence to GLP1 medicines or necessity of every proposedAMPK site." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 43, "pmid": "31706105", "title": "Berberine increases glucose uptake and intracellular ROS levels by promoting Sirtuin 3 ubiquitination.", "citation": "Li W, Li D, Kuang H et al. Berberine increases glucose uptake and intracellular ROS levels by promoting Sirtuin 3 ubiquitination. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020.", "doi": "10.1016/j.biopha.2019.109563", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31706105/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31706105/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID31706105", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Ovarian KGN cells showed glucose uptake together with SIRT3 ubiquitination, mitochondrial depolarization/complexI inhibition and dose-related ROS/apoptosis signals.", "what_it_does_not_show": "Transformed ovarian-cell concentrations cannot demonstrate human T2D efficacy or systemic toxicity; beneficial glucose uptake and adverse cell effects need exposure translation.", "confounders_present": [ "Transformed ovarian-cell concentrations cannot demonstrate human T2D efficacy or systemic toxicity; beneficial glucose uptake and adverse cell effects need exposure translation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 44, "pmid": "29467344", "title": "Berberine inhibits glucose oxidation and insulin secretion in rat islets.", "citation": "Bai M, Liu Y, Zhou F et al. Berberine inhibits glucose oxidation and insulin secretion in rat islets. Endocrine journal. 2018.", "doi": "10.1507/endocrj.EJ17-0543", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29467344/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29467344/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29467344", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M3" ], "evidence_class": "Moderate", "system": "ex vivo", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Rat islets berberine inhibited glucose-stimulated secretion/OCR; inhibition disappeared at25mM glucose and compoundC did not reverse OCR effect.", "what_it_does_not_show": "Context-dependent secretion conflicts with an unconditional secretagogue narrative; isolated islet result not clinical efficacy falsification or chronic human toxicity.", "confounders_present": [ "Context-dependent secretion conflicts with an unconditional secretagogue narrative; isolated islet result not clinical efficacy falsification or chronic human toxicity." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 45, "pmid": "26252777", "title": "Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.", "citation": "Yan HM, Xia MF, Wang Y et al. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one. 2015.", "doi": "10.1371/journal.pone.0134172", "pmcid": "PMC4529214", "url": "https://pubmed.ncbi.nlm.nih.gov/26252777/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26252777/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "NAFLD_NCT00633282", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "184 NAFLD patients randomized open-label lifestyle/pluspioglitazone/plusberberine16weeks; liverfat and weight/IR improved, measured berberine exposure and animal liver studies.", "what_it_does_not_show": "Different NAFLD eligibility, common lifestyle and openlabel design; not all participants established T2D or GLP1 comparators; no unique human hepatic mechanism.", "confounders_present": [ "Different NAFLD eligibility, common lifestyle and openlabel design; not all participants established T2D or GLP1 comparators; no unique human hepatic mechanism." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 46, "pmid": "20953398", "title": "Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism.", "citation": "Zhang Q, Xiao X, Feng K et al. Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism. Evidence-based complementary and alternative medicine : eCAM. 2011.", "doi": "10.1155/2011/924851", "pmcid": "PMC2952334", "url": "https://pubmed.ncbi.nlm.nih.gov/20953398/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20953398/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20953398", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "KKAy mice randomized berberine250mg/kg/day or control; glucose/IR/lipids improved with altered skeletal-muscle transcript profile.", "what_it_does_not_show": "Transcript changes nominate multiple mechanisms without necessity/rescue; single-species treatment does not qualify chronic human mechanism inference.", "confounders_present": [ "Transcript changes nominate multiple mechanisms without necessity/rescue; single-species treatment does not qualify chronic human mechanism inference." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 47, "pmid": "30409838", "title": "Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation.", "citation": "Tian Y, Cai J, Gui W et al. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation. Drug metabolism and disposition: the biological fate of chemicals. 2019.", "doi": "10.1124/dmd.118.083691", "pmcid": "PMC6323626", "url": "https://pubmed.ncbi.nlm.nih.gov/30409838/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30409838/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30409838", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Five-day mouse/in vitro bacterial exposure altered Clostridia/BSH/bile acids and intestinalFXR-associated signals.", "what_it_does_not_show": "Short microbial/metabolite perturbation without matched human glycemic dependency; not proven single mediator of clinical benefit.", "confounders_present": [ "Short microbial/metabolite perturbation without matched human glycemic dependency; not proven single mediator of clinical benefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 48, "pmid": "17971514", "title": "Berberine improves glucose metabolism through induction of glycolysis.", "citation": "Yin J, Gao Z, Liu D et al. Berberine improves glucose metabolism through induction of glycolysis. American journal of physiology. Endocrinology and metabolism. 2008.", "doi": "10.1152/ajpendo.00211.2007", "pmcid": "PMC2464622", "url": "https://pubmed.ncbi.nlm.nih.gov/17971514/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17971514/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID17971514", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Five-week obese-rat treatment improved IR; multiple cell lines increased glycolysis/AMPATP while oxygen consumption declined andAMPK rose.", "what_it_does_not_show": "Energy-stress response and cell glucose consumption do not establish human endocrine mechanism; no direct chronicT2D complication endpoint.", "confounders_present": [ "Energy-stress response and cell glucose consumption do not establish human endocrine mechanism; no direct chronicT2D complication endpoint." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 49, "pmid": "26174047", "title": "Transforming berberine into its intestine-absorbable form by the gut microbiota.", "citation": "Feng R, Shou JW, Zhao ZX et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Scientific reports. 2015.", "doi": "10.1038/srep12155", "pmcid": "PMC4502414", "url": "https://pubmed.ncbi.nlm.nih.gov/26174047/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26174047/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID26174047", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Gut bacteria reduced berberine into more absorbable dihydroberberine; antibiotics lowered conversion/exposure and lipid/glucose effects in KKAy mice.", "what_it_does_not_show": "Broad antibiotics alter many processes; absorbed metabolite mechanism and animal doses cannot alone prove human microbiome-specific causal mediation.", "confounders_present": [ "Broad antibiotics alter many processes; absorbed metabolite mechanism and animal doses cannot alone prove human microbiome-specific causal mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 50, "pmid": "18511510", "title": "Berberine acutely inhibits insulin secretion from beta-cells through 3',5'-cyclic adenosine 5'-monophosphate signaling pathway.", "citation": "Zhou L, Wang X, Shao L et al. Berberine acutely inhibits insulin secretion from beta-cells through 3',5'-cyclic adenosine 5'-monophosphate signaling pathway. Endocrinology. 2008.", "doi": "10.1210/en.2007-1752", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/18511510/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18511510/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18511510", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "Six-week high-fat-rat treatment improved glucose while lowering insulin; acuteislet/MIN6 berberine inhibited secretion,24hourpretreatment improved response and attenuated glucolipotoxicity.", "what_it_does_not_show": "Time/glucose-dependent secretion reversals preclude a universal single-direction secretagogue narrative; culture effects not chronic clinical harm.", "confounders_present": [ "Time/glucose-dependent secretion reversals preclude a universal single-direction secretagogue narrative; culture effects not chronic clinical harm." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 51, "pmid": "19208854", "title": "Berberine suppresses proinflammatory responses through AMPK activation in macrophages.", "citation": "Jeong HW, Hsu KC, Lee JW et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. American journal of physiology. Endocrinology and metabolism. 2009.", "doi": "10.1152/ajpendo.90599.2008", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19208854/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19208854/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19208854", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Obese-mouse adipose and isolatedmacrophage inflammation decreased; compoundC/dominant-negativeAMPK abolished cellular anti-inflammatory effects.", "what_it_does_not_show": "Cell-specific inhibition and inflammatory markers do not establish clinical T2D mediation, mortality benefit, or exact-stack safety.", "confounders_present": [ "Cell-specific inhibition and inflammatory markers do not establish clinical T2D mediation, mortality benefit, or exact-stack safety." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 52, "pmid": "33183320", "title": "Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia.", "citation": "Di Bisceglie AM, Watts GF, Lavin P et al. Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. Lipids in health and disease. 2020.", "doi": "10.1186/s12944-020-01406-4", "pmcid": "PMC7661247", "url": "https://pubmed.ncbi.nlm.nih.gov/33183320/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33183320/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "HTD1801_NCT03381287", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "50 hyperlipidemia patients randomized28days dose-ranging BUDCA/placebo; highdoseLDL lowered10.4%, with shorttermPK/tolerability foundation.", "what_it_does_not_show": "Not baselineT2D, ordinary berberine,12weeks, or event reduction; no GLP1 equivalence.", "confounders_present": [ "Not baselineT2D, ordinary berberine,12weeks, or event reduction; no GLP1 equivalence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 53, "pmid": "26167077", "title": "Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats.", "citation": "Jiang SJ, Dong H, Li JB et al. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World journal of gastroenterology. 2015.", "doi": "10.3748/wjg.v21.i25.7777", "pmcid": "PMC4491964", "url": "https://pubmed.ncbi.nlm.nih.gov/26167077/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26167077/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID26167077", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "40rats randomized normal/diabetic/drug groups;12week berberine improved glucose/IR and LKB1AMPKTORC2 markers versus diabetic model.", "what_it_does_not_show": "No pathway-specific genetic rescue and disease induction/doses differ from humanT2D; protein covariance not necessary mediator.", "confounders_present": [ "No pathway-specific genetic rescue and disease induction/doses differ from humanT2D; protein covariance not necessary mediator." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 54, "pmid": "20036710", "title": "Berberine modulates insulin signaling transduction in insulin-resistant cells.", "citation": "Liu LZ, Cheung SC, Lan LL et al. Berberine modulates insulin signaling transduction in insulin-resistant cells. Molecular and cellular endocrinology. 2010.", "doi": "10.1016/j.mce.2009.12.027", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20036710/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20036710/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20036710", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Weak", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Insulin-resistant ratmuscle cells showed enhancedGLUT4/glucose uptake and IRS1/PKC/mTOR-related signaling withberberine.", "what_it_does_not_show": "Cellculture metabolic rescue does not establish human chronic clinical causality; multiple route changes not necessity of a single pathway.", "confounders_present": [ "Cellculture metabolic rescue does not establish human chronic clinical causality; multiple route changes not necessity of a single pathway." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 55, "pmid": "24791752", "title": "Randomized controlled trial of oral glutathione supplementation on body stores of glutathione.", "citation": "Richie JP, Nichenametla S, Neidig W et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European journal of nutrition. 2015.", "doi": "10.1007/s00394-014-0706-z", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24791752/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24791752/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24791752", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M4" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "54healthy adults randomized6months oralglutathione/placebo; GSHstores increased, washedout, immune-marker subset signal.", "what_it_does_not_show": "Target engagement and antioxidant ratios are not functionalnetbenefit of berberine/GSH/NMN stack or diabetes treatment.", "confounders_present": [ "Target engagement and antioxidant ratios are not functionalnetbenefit of berberine/GSH/NMN stack or diabetes treatment." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 56, "pmid": "36740954", "title": "Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study.", "citation": "Pencina KM, Valderrabano R, Wipper B et al. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. The Journal of clinical endocrinology and metabolism. 2023.", "doi": "10.1210/clinem/dgad027", "pmcid": "PMC11491622", "url": "https://pubmed.ncbi.nlm.nih.gov/36740954/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36740954/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MIB626_28day_physiology", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "30overweight older adults randomized28days NMN/placebo; NAD,weight,lipid/diastolic signals improved but insulin sensitivity,physicalperformance and hepatic/intraabdominalfat null.", "what_it_does_not_show": "Short small ingredienttrial with many endpoints; no exactstack or durable outcome, and NAD rise not equivalent functional rejuvenation.", "confounders_present": [ "Short small ingredienttrial with many endpoints; no exactstack or durable outcome, and NAD rise not equivalent functional rejuvenation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 57, "pmid": "35927255", "title": "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men.", "citation": "Igarashi M, Nakagawa-Nagahama Y, Miura M et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj aging. 2022.", "doi": "10.1038/s41514-022-00084-z", "pmcid": "PMC9158788", "url": "https://pubmed.ncbi.nlm.nih.gov/35927255/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35927255/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35927255", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Olderhealthy men randomized6/12weekNMN; NAD rise and nominal gait/leftgrip gains, bodycomposition null.", "what_it_does_not_show": "Nominal selective outcomes need replication; no exactstack, T2D clinical endpoint, or agingtrajectory inference.", "confounders_present": [ "Nominal selective outcomes need replication; no exactstack, T2D clinical endpoint, or agingtrajectory inference." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 58, "pmid": "35479740", "title": "Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects.", "citation": "Okabe K, Yaku K, Uchida Y et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Frontiers in nutrition. 2022.", "doi": "10.3389/fnut.2022.868640", "pmcid": "PMC9036060", "url": "https://pubmed.ncbi.nlm.nih.gov/35479740/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35479740/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35479740", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Thirty healthy adults randomizedNMN250mg/placebo12weeks; NAD/NAMN increased, routine physiological/laboratory measures showed no major adverse signal.", "what_it_does_not_show": "Bloodtarget engagement and short safety do not establish functional benefit, lifelong safety, or triple-stack efficacy.", "confounders_present": [ "Bloodtarget engagement and short safety do not establish functional benefit, lifelong safety, or triple-stack efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 59, "pmid": "36797393", "title": "Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial.", "citation": "Katayoshi T, Uehata S, Nakashima N et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Scientific reports. 2023.", "doi": "10.1038/s41598-023-29787-3", "pmcid": "PMC9935856", "url": "https://pubmed.ncbi.nlm.nih.gov/36797393/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36797393/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36797393", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "36healthy middle-aged adults randomized12weekNMN; serum nicotinamide increased but pulsewavevelocity difference nonsignificant.", "what_it_does_not_show": "Trend cannot substitute for between-arm arterialfunction benefit; no exactstack or disease events.", "confounders_present": [ "Trend cannot substitute for between-arm arterialfunction benefit; no exactstack or disease events." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 60, "pmid": "36002548", "title": "Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women.", "citation": "Fukamizu Y, Uchida Y, Shigekawa A et al. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Scientific reports. 2022.", "doi": "10.1038/s41598-022-18272-y", "pmcid": "PMC9400576", "url": "https://pubmed.ncbi.nlm.nih.gov/36002548/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36002548/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36002548", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "31healthy adults randomized1250mg/dayNMN/placebo4weeks; no severe adverseevents or out-of-range physiologic changes.", "what_it_does_not_show": "Small short-term safety study cannot establish chronic safety or exact-stack netbenefit.", "confounders_present": [ "Small short-term safety study cannot establish chronic safety or exact-stack netbenefit." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 61, "pmid": "20298851", "title": "Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics.", "citation": "Gu Y, Zhang Y, Shi X et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta. 2010.", "doi": "10.1016/j.talanta.2010.01.015", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/20298851/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/20298851/", "tier": "A", "source_tier": "A", "kind": "trial_metabolomic_report", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Zhang_T2D_dyslipidemia_2008", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "60T2D/dyslipidemia samples berberine/placebo metabolomics showed reductions in freefattyacids and treatment-separated profiles.", "what_it_does_not_show": "Likely related to2008Zhang diabetes cohort; conservatively grouped until provenindependent. Metabolic covariance not causalmediator or new HbA1c clinicaltrial.", "confounders_present": [ "Likely related to2008Zhang diabetes cohort; conservatively grouped until provenindependent. Metabolic covariance not causalmediator or new HbA1c clinicaltrial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "Related T2D/dyslipidemia placebo metabolomics may reuse the earlier Zhang cohort. Conservatively not treated as independent efficacy replication until parent independence is verified." ] }, { "n": 62, "pmid": "41882153", "title": "Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization.", "citation": "Zhao JV, Sarsani V, Chen B et al. Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization. NPJ cardiovascular health. 2026.", "doi": "10.1038/s44325-026-00113-w", "pmcid": "PMC13018313", "url": "https://pubmed.ncbi.nlm.nih.gov/41882153/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41882153/", "tier": "A", "source_tier": "A", "kind": "trial_signature_cohort_and_mendelian_randomization", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Berberine_signature_NCT03770325_and_UKBiobank", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "natural experiment", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "2026original built berberine-response proteomic/hormone signature from RCT and linked it to IHD/diabetes via UKBiobank and MR; signalOR.85IHD/.88diabetes.", "what_it_does_not_show": "Genetic instrument is a derived signature rather than assigned oralberberine exposure; does not demonstrate clinicalevent treatmentbenefit or GLP1 noninferiority. Cohort/MRcomponents not counted as multiple independentT2D drugtrials.", "confounders_present": [ "Genetic instrument is a derived signature rather than assigned oralberberine exposure; does not demonstrate clinicalevent treatmentbenefit or GLP1 noninferiority. Cohort/MRcomponents not counted as multiple independentT2D drugtrials." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "Derived proteomic/hormone signature plus UKBiobank outcome instruments; no direct randomized clinical event trial of oral berberine." ] }, { "n": 63, "pmid": "39107107", "title": "Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes.", "citation": "Nikseresht M, Dabidi Roshan V, Nasiri K. Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes. Physiological reports. 2024.", "doi": "10.14814/phy2.16146", "pmcid": "PMC11303016", "url": "https://pubmed.ncbi.nlm.nih.gov/39107107/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39107107/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39107107", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "54overweight prediabetic men randomized6groups8weeks HIIT/berberine combinations; exercise benefitedglucose/IR, addingberberine did not addbenefit; berberine-only within-armchanges.", "what_it_does_not_show": "Prediabeteslabel with unusuallybroad110–180mg/dL FBG reported and8weeks outside registeredeligibility; within-armchange not treatmentcontrast. No GLP1 headtohead.", "confounders_present": [ "Prediabeteslabel with unusuallybroad110–180mg/dL FBG reported and8weeks outside registeredeligibility; within-armchange not treatmentcontrast. No GLP1 headtohead." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 68, "verified": 68, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.", "specific_trigger": "Exposure and candidate pathway engagement are supported by human PK, the acute healthy-human KCNH6 clamp, PREMOTE microbial/metabolite analyses and causal perturbations in mice and cells. These demonstrate plausible multiple routes, but do not isolate a unique endogenous mechanism for chronic human T2D benefit. Model specificity and biomarker-to-human mediation inferences remain Γ; the actual drug treatment effect is scored separately.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC3", "cap": "Α", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Use when the hypothesis is mostly a grand narrative with weak intervention support.", "specific_trigger": "No examined direct, matched, powered noninferiority comparison establishes berberine equivalence to modern GLP-1 medicines for weight loss or cardiometabolic outcomes. Metformin pilot similarity, short antipsychotic-weight studies and BUDCA biomarker effects are different interventions or contexts. The large six-month diabetes-free obesity trial was null for visceral and liver fat and body composition. Exact class-equivalence claims remain Α, without treating absence of a direct comparison as proof of inferiority on every outcome.", "resulting_ceiling": "Α" }, { "subclaim_id": "SC4", "cap": "Α", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Use when the hypothesis is mostly a grand narrative with weak intervention support.", "specific_trigger": "No examined trial tests the exact berberine, glutathione and NMN combination with clinical or functional net benefit and component-dismantling controls. Ingredient-specific NAD, glutathione and short functional findings are real but do not establish a triple-stack interaction or long-term safety. Exact stack-benefit claims remain Α; this does not negate separate ingredient effects.", "resulting_ceiling": "Α" } ], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Oral berberine improves glycemic control in adults with type 2 diabetes.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "Literal rubric06 aging thresholds are preserved and disclosed, while the preregistered clinical adaptation assesses the actual diabetes-treatment phenotype. HbA1c plus glucose control can cross the clinical threshold without a lifespan trial. The marker cap still binds inference to cardiovascular events, functional improvement, longevity or unique mediation. Positive mouse pathway dependency crosses within its actual model but does not automatically become chronic human dependency. A derived MR signature is considered on its assumptions without being equated to an instrument of oral drug exposure; no weak-leg cap is reapplied to a genuinely convergent exact-scope set.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "Biomarker-only improvement without organismal benefit", "Single-species or single-strain evidence" ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Exposure and candidate pathway engagement are supported by human PK, the acute healthy-human KCNH6 clamp, PREMOTE microbial/metabolite analyses and causal perturbations in mice and cells. These demonstrate plausible multiple routes, but do not isolate a unique endogenous mechanism for chronic human T2D benefit. Model specificity and biomarker-to-human mediation inferences remain Γ; the actual drug treatment effect is scored separately.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID33024120, PMID18397984", "gamma_hard_rules_triggered": [], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "PREMOTE provides a verified twelve-week, concealed, double-blind placebo comparison in drug-naive T2D adults with synthesized berberine 1.2g/day. HbA1c fell by0.99 versus0.59 percentage points; the incremental effect is approximately0.40 percentage points rather than the entire within-arm fall. The older 116-person placebo-controlled three-month trial also supports a glycemic effect. With the explicit clinical-phenotype adaptation, these positive randomized comparisons cross Δ for the registered glycemic-control phenotype. Durable treatment effects across the full range of baseline T2D, products and co-medication have not been mapped. Diabetes-free adiposity nulls do not manufacture an Ε boundary within the registered T2D scope.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "No direct modern GLP-1 noninferiority comparison" ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "No examined direct, matched, powered noninferiority comparison establishes berberine equivalence to modern GLP-1 medicines for weight loss or cardiometabolic outcomes. Metformin pilot similarity, short antipsychotic-weight studies and BUDCA biomarker effects are different interventions or contexts. The large six-month diabetes-free obesity trial was null for visceral and liver fat and body composition. Exact class-equivalence claims remain Α, without treating absence of a direct comparison as proof of inferiority on every outcome.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "No exact combination and component-dismantling clinical trial" ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "No examined trial tests the exact berberine, glutathione and NMN combination with clinical or functional net benefit and component-dismantling controls. Ingredient-specific NAD, glutathione and short functional findings are real but do not establish a triple-stack interaction or long-term safety. Exact stack-benefit claims remain Α; this does not negate separate ingredient effects.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Use exposure-matched human or disease-relevant mediator dissociation/rescue to identify a chronic T2D pathway separately from treatment efficacy, accounting for pathway compensation and multiple routes." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "yes", "supporting_evidence": [ "[1] PREMOTE randomized drug-naive newly diagnosed T2D patients to synthesized berberine 1.2g daily or matched placebo for12weeks after common gentamicin pretreatment; original Methods verify concealed age-stratified allocation and blinding. HbA1c reduction -0.99 vs-0.59 percentage points; more GI adverse events. Original Results391/409 primary-analysis participants; probiotic addition did not improve HbA1c.", "[3] 116 T2D/dyslipidemia patients randomly allocated berberine1g daily or placebo for3months; HbA1c7.5 to6.6 and fasting/postload glucose improvements differed significantly from placebo; constipation in5." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ε", "requirement_quoted": "Requires causal effect in constrained contexts, backgrounds, or species.", "satisfied": "no", "supporting_evidence": [ "[1] PREMOTE randomized drug-naive newly diagnosed T2D patients to synthesized berberine 1.2g daily or matched placebo for12weeks after common gentamicin pretreatment; original Methods verify concealed age-stratified allocation and blinding. HbA1c reduction -0.99 vs-0.59 percentage points; more GI adverse events. Original Results391/409 primary-analysis participants; probiotic addition did not improve HbA1c.", "[3] 116 T2D/dyslipidemia patients randomly allocated berberine1g daily or placebo for3months; HbA1c7.5 to6.6 and fasting/postload glucose improvements differed significantly from placebo; constipation in5." ], "what_would_cross_it": "Prespecify tests across baseline T2D severity, co-medication and product contexts with adequate duration and verified ordinary-berberine exposure. A mapped in-scope positive/null boundary would support Ε; an independently failing exact-phenotype causal line would be needed for Ζ." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Conduct powered direct modern GLP-1 noninferiority trials with prespecified margins for weight, clinical outcomes, adherence, tolerability and follow-up; indirect biomarker resemblance cannot cross the equivalence threshold." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Test the exact triple stack against placebo and single-/dual-component arms with prespecified clinical/function outcomes and sufficient interaction/safety follow-up; target engagement alone cannot demonstrate net benefit." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "no", "internal_negative_controls": [ "PREMOTE probiotics-only arm did not improve HbA1c beyond placebo; adding probiotics did not improve HbA1c beyond berberine alone, PMID33024120", "Six-month diabetes-free obesity/MASLD trial: adiposity, liver fat, HbA1c and body-composition nulls, PMID41543854", "Berberis fruit extract HbA1c between-arm null, PMID24250489", "Prediabetes HIIT trial had no added benefit from berberine, PMID39107107", "Acute rat-islet secretion inhibition with glucose-dependent reversal, PMID29467344", "No metabolic phenotype transfer by fecal transplantation in a mouse study, PMID33994854", "NMN primary stepping endpoint null, PMID38789831; physical performance and insulin sensitivity nulls, PMID36740954" ], "note": "Clinical, prediabetes, obesity, liver, PCOS and drug-induced weight contexts were tested, but they do not establish a prospectively mapped boundary within the exact registered pure-berberine, twelve-week adult T2D glycemic claim. Diabetes-free nulls are external scope limits, not a failure inside baseline T2D. Antibiotic pretreatment, ethnicity, formulation, concomitant therapy and durability remain generalization questions. Tolerance-run-in or adherent completers do not redefine broad beneficiaries after outcomes." }, "falsification_patterns_met": [], "pitfalls_flagged": [ { "pitfall": "Therapeutic effect misread as mechanistic proof", "where": "Randomized HbA1c benefit demonstrates a treatment effect, not unique microbiome, AMPK, insulin-receptor or KCNH6 mediation." }, { "pitfall": "Confirmation by biomarker", "where": "Blood NAD, glutathione, LDL and predicted-risk movement cannot substitute for stack function, cardiovascular events or longevity." }, { "pitfall": "Mechanism conflation", "where": "Ordinary berberine differs from BUDCA, fruit extract, goldenseal and berberine/cinnamon bundles; endogenous GLP-1 signaling does not establish prescription GLP-1 equivalence." }, { "pitfall": "Scope fitted to the result", "where": "Diabetes-free obesity nulls are outside baseline T2D; tolerant-run-in selection and completer analyses do not justify universal all-comer safety or responder-defined benefit." }, { "pitfall": "Replication confused with reproduction", "where": "PREMOTE lipid follow-up is the same parent trial; related metabolomic reports and reused signatures do not add independent drug efficacy lines." }, { "pitfall": "Association dressed as mechanism", "where": "Microbial or metabolite covariance and a genetically instrumented drug-response signature do not directly perturb assigned oral exposure or prove clinical event mediation." } ], "causal_tally_audit": { "tally_claimed_by_document": 2, "tally_after_audit": 2, "tally_unit": "Positive qualifying study units across scoped subclaims, not independent causal lines or full-claim necessity/sufficiency.", "screened_discriminating_contrasts": 2, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "Two positive ordinary-berberine clinical study units supply SC2 threshold credit; this is not two independently failing lines or sixty-three clinical efficacy trials.", "BUDCA, botanical extracts, bundles, prediabetes, PCOS, obesity and acute healthy-human studies remain separate scopes.", "PREMOTE follow-up, related metabolomics, correction notices and provider citations do not inflate trial independence or examined-original counts.", "Ingredient-specific clinical signals do not count as positive exact triple-stack perturbations." ] }, "steelman": { "case_one_rung_higher": "The strongest Ε case combines replicated positive placebo trials with null results in diabetes-free obesity and prediabetic exercise settings, suggesting baseline metabolic context determines efficacy. PREMOTE's matched probiotic controls and distinct mechanistic studies further narrow explanations. This is a substantial argument for context-specific effects in the broader topic family.", "case_one_rung_lower": "The strongest Γ case applies the literal aging-rubric biomarker-only rule to HbA1c and points to short studies, antibiotic pretreatment and unresolved mediation. That case would be persuasive for cardiovascular protection, rejuvenation or a unique mechanism inferred from glycemic markers. It is less persuasive for the preregistered treatment phenotype itself.", "which_rejected": "The higher case is rejected for the exact lead: diabetes-free/preclinical nulls do not map a failure boundary inside baseline T2D, and chronic product/co-medication/duration generalization remains largely untested. The lower case is rejected because the clinical adaptation was explicit before outcome appraisal, and a verified concealed placebo trial directly improves the registered glycemic phenotype. The decision does not extend Δ to hard complications, longevity or unique endogenous mediation.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: Run a multisite, baseline-stratified, double-blind trial of chemically verified ordinary oral berberine versus matching placebo added to unchanged standard T2D care, with prespecified twelve-month glycemic durability and adverse-event outcomes. Include strata for baseline HbA1c, disease duration and fixed co-medication; avoid routine antibiotic pretreatment or randomize that factor separately if mechanistically essential. Add prespecified pathway measurements and an orthogonal mediator-dissociation component rather than declaring correlated microbiome changes necessary. Evaluate GLP-1 equivalence and the exact triple stack in separate properly controlled trials." }, "final_score": { "hsef_level": "Δ", "hsef_descriptor": "First field-valid causal perturbation crossed", "confidence": "Moderate", "confidence_rationale": "63 primary reports with 4 selected partial-body examinations; density, heterogeneous controls and methodological heterogeneity set the confidence, not correctness and not the reviewer's access depth. Re-tested against the High band text, which requires extensive independent replication across labs, models and assay modalities: the band holds at Moderate.", "rests_on_non_peer_reviewed_work": false, "rationale": "The preregistered primary-subclaim rule returns Δ from SC2: defined oral berberine has a positive controlled treatment effect on twelve-week T2D glycemic control. The claim is deliberately narrower than weight loss, GLP-1 equivalence, complication prevention or rejuvenation stacks. Sixty-three original reports include clinical efficacy, exposure and interaction studies, relevant model experiments and companion ingredients; they are not sixty-three isolated T2D efficacy trials. Weakest-link returns Α because the separate equivalence and exact-stack companions lack direct evidence; primary-subclaim and scope-matched return Δ. Repeated trials increase confidence but do not automatically become independently failing causal lines or identify a unique mediator." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": 5, "derivation": "For the beneficial glycemic-control trajectory, positive randomized ordinary-berberine versus placebo treatment demonstrates a causal contribution, so the no-dependency Step2 does not apply. Neither necessity/primacy nor a required permissive condition is demonstrated. Step5 therefore describes an exposure that reinforces or stabilizes glycemic control in established T2D. This therapeutic direction does not imply that berberine reinforces diabetes or that one candidate endogenous pathway initiates the disease.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "Recent KCNH6, response-signature and formulation studies examine mechanisms or different products (PMID34556670,41882153,40029660). BUDCA trials cannot be silently substituted for a verified pending ordinary-berberine long-term glycemic result.", "justification": "Recent KCNH6, response-signature and formulation studies examine mechanisms or different products (PMID34556670,41882153,40029660). BUDCA trials cannot be silently substituted for a verified pending ordinary-berberine long-term glycemic result." }, "stability": { "value": "Stable", "trigger": "No verified named pending exact ordinary-berberine result was identified that determines the full-scope letter. A prespecified durable T2D placebo trial across baseline treatment contexts is a concrete upward/generalization trigger; existing BUDCA development is distinct.", "justification": "No verified named pending exact ordinary-berberine result was identified that determines the full-scope letter. A prespecified durable T2D placebo trial across baseline treatment contexts is a concrete upward/generalization trigger; existing BUDCA development is distinct." }, "divergence": { "implied_level": null, "implied_level_basis": "No single field-implied level is defensible from conflicting framings.", "assessed_level": "Δ", "gap_in_rungs": null, "value": "Contested", "justification": "The two framings carry different implied levels, so no single implied level and no arithmetic gap can be stated. Consumer and supplement-channel framing presents the compound as interchangeable with prescription GLP-1 medicines and as a broad weight-loss and rejuvenation agent, which would imply a level well above the assessed Δ for SC3 and SC4; the controlled-trial literature cited here presents a modest short-term HbA1c effect of uncertain durability, which is approximately aligned with Δ for SC2. No manufactured field consensus is asserted." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "none assigned", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": true, "new_level": "Δ", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "Run a multisite, baseline-stratified, double-blind trial of chemically verified ordinary oral berberine versus matching placebo added to unchanged standard T2D care, with prespecified twelve-month glycemic durability and adverse-event outcomes. Include strata for baseline HbA1c, disease duration and fixed co-medication; avoid routine antibiotic pretreatment or randomize that factor separately if mechanistically essential. Add prespecified pathway measurements and an orthogonal mediator-dissociation component rather than declaring correlated microbiome changes necessary. Evaluate GLP-1 equivalence and the exact triple stack in separate properly controlled trials.", "readout": "HbA1c and continuous/fasting glucose treatment contrasts, hypoglycemia, GI tolerability, adherence, interactions, medication rescue and durability; hard complications assessed separately if powered", "critical_control": "Matching placebo, concealed allocation, verified product/dose, stable background care, prespecified baseline strata, blinded laboratory measurements and complete intention-to-treat follow-up", "supporting_result": "Durable incremental clinical glycemic benefit across prospectively defined T2D contexts with acceptable safety; mediator dissociation independently narrows mechanism", "falsifying_result": "No incremental glycemic effect despite verified exposure and adherence, or benefit explained by unequal rescue/co-medication; harms or durable loss of effect retained in the analysis" } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Durable ordinary-berberine efficacy and safety beyond short T2D trials under contemporary unchanged standard care", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Role of common antibiotic pretreatment and baseline microbial ecology in the PREMOTE response", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "Exposure/product standardization and translation between ordinary berberine, BUDCA and botanical bundles", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "Unique chronic human mediation versus simultaneous gut, secretion, receptor and mitochondrial effects", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 5", "statement": "Direct modern GLP-1 equivalence for specified weight and cardiometabolic outcomes", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 6", "statement": "Exact triple-stack trials and component-dismantling evidence with meaningful functional outcomes", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 7", "statement": "Drug interactions, formulation variability and all-comer tolerability beyond selected short-term cohorts", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-13", "reviewer": "Codex", "evidence_base_note": "63 primary reports; literature cutoff 2026-10-13; source examination UTC date 2026-10-13; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Entrez, separately logged public original-body retrieval, and Consensus Pro browser searches. Provider output retained as observed browser text with citation-link mappings, or as previously exported connector documents where present. AI synthesis is not primary full-text verification. Consensus retrieved/included counts are not examined-primary counts. Scite monthly limit was reached earlier in this session; no new Scite query or incoming citation-context audit is claimed for these cases. Tool receipts record actual use. Supplementary discovery outputs do not earn primary-count credit. No independent blinded review.", "skill_version": "5.3", "validator_run": "PASS: exact archived HSEF v5.3 validator rerun after final sealing.", "validator_warnings_addressed": "No warnings.", "limits": "Bounded source-based critical review; no complete-paper/supplement audit, independent scientific peer review or blinded calibration. Revision cases retain original prose outside the three framework output blocks and have explicit correction logs." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "These topic families were selected from an editorial traffic-priority list. Selection was visible; no blind calibration or predetermined clinical verdict was preregistered." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": true, "why_not_sufficient": "Replicated oral-drug RCTs were considered but share pharmacologic exposure, product, adherence and comparator failure possibilities. The derived signature MR (PMID41882153) is informative yet genetically perturbs a response-associated protein/hormone pattern rather than assigned oral berberine; it does not independently establish the exact twelve-week T2D phenotype. Mouse knockout and human acute secretion constrain mechanisms but do not provide an independent chronic clinical causal line. No convergence is denied merely because one component is observational; the exact-scope independently failing conjunction is unverified." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "Replicated oral-drug RCTs were considered but share pharmacologic exposure, product, adherence and comparator failure possibilities. The derived signature MR (PMID41882153) is informative yet genetically perturbs a response-associated protein/hormone pattern rather than assigned oral berberine; it does not independently establish the exact twelve-week T2D phenotype. Mouse knockout and human acute secretion constrain mechanisms but do not provide an independent chronic clinical causal line. No convergence is denied merely because one component is observational; the exact-scope independently failing conjunction is unverified." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "Replicated oral-drug RCTs were considered but share pharmacologic exposure, product, adherence and comparator failure possibilities. The derived signature MR (PMID41882153) is informative yet genetically perturbs a response-associated protein/hormone pattern rather than assigned oral berberine; it does not independently establish the exact twelve-week T2D phenotype. Mouse knockout and human acute secretion constrain mechanisms but do not provide an independent chronic clinical causal line. No convergence is denied merely because one component is observational; the exact-scope independently failing conjunction is unverified." }, { "kind": "withdrawal_rechallenge", "available": false, "why_not_sufficient": "Replicated oral-drug RCTs were considered but share pharmacologic exposure, product, adherence and comparator failure possibilities. The derived signature MR (PMID41882153) is informative yet genetically perturbs a response-associated protein/hormone pattern rather than assigned oral berberine; it does not independently establish the exact twelve-week T2D phenotype. Mouse knockout and human acute secretion constrain mechanisms but do not provide an independent chronic clinical causal line. No convergence is denied merely because one component is observational; the exact-scope independently failing conjunction is unverified." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": false, "why_not_sufficient": "Replicated oral-drug RCTs were considered but share pharmacologic exposure, product, adherence and comparator failure possibilities. The derived signature MR (PMID41882153) is informative yet genetically perturbs a response-associated protein/hormone pattern rather than assigned oral berberine; it does not independently establish the exact twelve-week T2D phenotype. Mouse knockout and human acute secretion constrain mechanisms but do not provide an independent chronic clinical causal line. No convergence is denied merely because one component is observational; the exact-scope independently failing conjunction is unverified." } ], "convergence_present": false, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 63, "claims_total": 68, "claims_verified": 68, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 63, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "PREMOTE randomized drug-naive newly diagnosed T2D patients to synthesized berberine 1.2g daily or matched placebo for12weeks after common gentamicin pretreatment; original Methods verify concealed age-stratified allocation and blinding. HbA1c reduction -0.99 vs-0.59 percentage points; more GI adverse events. Original Results391/409 primary-analysis participants; probiotic addition did not improve HbA1c. Observed treatment effect is conditional on this antibiotic/lifestyle background and duration; microbial covariance does not prove unique human mediation or long-term complication benefit.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph9, 1:Results:paragraph17, 1:Results:paragraph18, 3:Methods:paragraph0, 3:Methods:paragraph1, 3:Methods:paragraph2, 3:Methods:paragraph55, 3:Methods:paragraph56, 3:Methods:paragraph76. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C2", "text": "Distinct HTD1801 berberine-ursodeoxycholate formulation113 randomized T2D patients for12weeks; original Methods/Results confirm matched placebo and placebo-adjusted HbA1c -0.4/-0.7 percentage points by dose; weight remained stable. BUDCA is a new combined molecular entity; benefit cannot be assigned to ordinary berberine alone or borrowed for GLP1 weight-loss equivalence. No cardiovascular event endpoint.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph3, 1:Methods:paragraph4, 2:Results:paragraph0, 2:Results:paragraph5, 2:Results:paragraph18, 2:Results:paragraph20. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C3", "text": "116 T2D/dyslipidemia patients randomly allocated berberine1g daily or placebo for3months; HbA1c7.5 to6.6 and fasting/postload glucose improvements differed significantly from placebo; constipation in5. Within-arm change is not the treatment difference; clamp disposal change did not differ significantly between arms P=.063. Abstract-level access does not verify every allocation/adherence detail or hard outcomes.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C4", "text": "34 prediabetic participants in12week double-blind pilot; branded berberine1.5g daily improved HbA1c and fasting/OGTT markers versus placebo. Baseline prediabetes is outside registered T2D scope; small pilot does not establish prevention of diabetes, GLP1 equivalence, or durable clinical outcomes.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C5", "text": "100 presumed NASH plus T2D participants randomized18weeks to BUDCA versus placebo; high-dose liver fat -4.8 vs-2.0%, glycemic and weight improvements reported. UDCA-containing ionic salt differs from pure berberine; liver-fat imaging and secondary glycemia do not establish biopsy resolution or class equivalence.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C6", "text": "12week double-blind T2D trial of berberine1.2g plus cinnamon600mg daily versus placebo reported lower fasting glucose and HbA1c but no anthropometric difference. No berberine-only or cinnamon-only dismantling arms; bundle effect cannot isolate berberine or validate the glutathione/NMN stack.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C7", "text": "50 randomized T2D patients received900mg berberine plus600mg fenugreek daily or placebo for12weeks; fasting-glucose/insulin between-arm signals and SF12 gains; HbA1c improvement reported within arm. Within-arm HbA1c is insufficient evidence of between-arm efficacy; no single-component arms or exact triple stack; small trial and many endpoints.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C8", "text": "31 T2D participants randomized3months to Berberis fruit extract3g daily or placebo; glucose/insulin and lipid effects positive while HbA1c showed no significant between-arm change. Fruit extract is multicomponent and dose not equivalent to isolated berberine; this null HbA1c does not falsify the pure-drug exposure hypothesis.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C9", "text": "StudyA36 newly diagnosed T2D adults randomized berberine versus metformin for3months with similar glycemic reductions; StudyB48 poorly controlled adults added berberine and HbA1c fell; GI effects34.5% across reported patients. Active-comparator pilot was not a powered noninferiority demonstration; uncontrolled add-on StudyB cannot isolate treatment effect. Metformin similarity is not modern GLP1 equivalence.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C10", "text": "T2D three-arm crossover goldenseal/metformin interaction study showed aggregate metforminAUC ratio.93 within no-effect band, but dose-dependent reductions around20% at lower metformin dose; HbA1c exploratory reduction. Goldenseal contains multiple alkaloids; brief PK does not establish pure-berberine12week efficacy or the absence of clinically important individual interactions.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C11", "text": "150 PCOS infertility patients randomized berberine/metformin/placebo beforeIVF; metabolic and pregnancy outcomes improved, with more live births than metformin reported. PCOS/IVF population and reproductive endpoints are outside T2D scope; no GLP1 comparator, weight-loss equivalence, or general pregnancy-safety demonstration.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C12", "text": "Human cell lines showed increased insulin-receptor expression and clinical T2D treatment HbA1c/fasting glucose reductions similar to metformin/rosiglitazone; peripheral lymphocyte receptor signal increased. Abstract does not report clinical duration or sufficient comparator/control detail for registered threshold credit; lymphocyte marker correlation does not isolate causal receptor mediation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C13", "text": "PhaseIb48 T2D/MASLD patients included treatment-naive cohorts and12 on stable metformin;28day HTD1801 exposure improved fasting/postprandial measures with tolerable short-term events. Only28days and distinct BUDCA formulation; retrospectively registered. Does not meet12week pure-berberine SC2 or demonstrate chronic safety.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C14", "text": "12week randomized add-on formulation berberine/hesperidin/chromium plus metformin improved HbA1c and fasting glucose versus metformin-only control. No ingredient dismantling, placebo masking not established in abstract, and composition differs from exact glutathione/NMN stack; relative HbA1c change not percentage-point effect.", "carries_number": true, "load_bearing_for": [ "SC2", "SC4" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C15", "text": "89 PCOS/IR women randomized berberine/metformin/placebo with common cyproterone for3months; metabolic and hormonal effects versus placebo. PCOS and common hormonal treatment differ from baseline T2D; metabolic marker effects do not establish GLP1 equivalence or cardiovascular benefit.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C16", "text": "65 schizophrenia patients on stable antipsychotic randomized8weeks;49 completed; berberine weight -1.10kg versus placebo+1.45kg, with leptin covariation. Attrition and distinct drug-induced weight-gain context; no baseline T2D requirement,12week observation, GLP1 head-to-head, or proof leptin mediates effect.", "carries_number": true, "load_bearing_for": [ "SC3" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C17", "text": "44 overweight adults randomized open-label diet versus multinutraceutical/protein-shake program13weeks; greater risk-factor/weight changes in bundle;12 discontinued beforeweek9. Diet and many ingredients changed together; authors cannot separate supplement from synergy. Predicted Framingham risk is not observed event reduction and exact triple stack untested.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C18", "text": "Post-botanical human plasma incubation predicted CYP inhibition better than artificial buffers and mirrored goldenseal clinical interactions. Method-development and multialkaloid exposures do not establish pure-berberine clinical net benefit; ex vivo assay is not a long-term stack safety trial.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C19", "text": "HepG2 LCMS identified phaseI/II berberine metabolites and intracellular enrichment of demethyleneberberine. Transformed cells and metabolite distribution cannot establish systemic target exposure, mechanism necessity, or clinical T2D glycemic efficacy.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C20", "text": "Two small healthy-male PK groups found no significant CsA change at6mg/kg but19.2% AUC increase at3mg/kg with berberine. Dose-specific interaction signal and proposed CYP/gastric mechanisms not isolated; does not quantify clinical transplant harms or safety of exact stack.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C21", "text": "Six healthy volunteers took multicomponent K601; berberine and other absorbed alkaloid PK measured, with apparent population differences. Tiny multicomponent influenza-preparation exposure study; no T2D outcome, no pure-drug pharmacodynamic mediation, and no population-wide ethnic PK inference.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C22", "text": "Randomized crossover repeated900mg/day berberine2weeks in healthy men decreased CYP2D6/2C9/3A4 activity; midazolamAUC about40% higher. Healthy-probe PK and short duration do not establish all-drug interactions or net long-term stack benefit; legitimate interaction evidence narrows simple safety narratives.", "carries_number": true, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C23", "text": "Caco2 transport experiments with Pgp/MRP inhibitors identify berberine as Pgp substrate and increased absorptive transport with inhibitors. Cell transport does not measure clinical bioavailability or disease phenotype; apparent paper-unit formatting retained rather than silently corrected.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C24", "text": "High-fat-fed hamsters showed higher gut nitroreductase, berberine absorption and lipid response; human hyperlipidemia PK correlated with fecal enzyme activity. Human correlation and hamster metabolic response do not establish human T2D microbial necessity; normal-diet lipid null is context specific, not a chronic glycemic boundary.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C25", "text": "24 older adults randomized16weeks GlyNAC versus alanine, with functional and molecular improvements; young comparison received2weeks. Glycine/NAC precursors are not direct glutathione and no berberine/NMN combination; small multi-endpoint experiment does not validate exact stack or lifespan extension.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C26", "text": "80 healthy middle-aged participants randomized60days NMN dose groups/placebo; NAD and6minute-walk gains, HOMAIR no significant difference; per-protocol analysis. Ingredient-specific short-term outcomes and biological-age algorithm do not establish exact-stack benefit, diabetes treatment, or aging reversal.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C27", "text": "10week double-blind NMN trial in overweight/obese postmenopausal prediabetic women improved clamp muscle glucose disposal and insulin signaling. No T2D berberine arm or triple stack; local muscle insulin sensitivity does not establish systemic clinical glycemic outcomes or mortality benefit.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C28", "text": "48 amateur runners randomized NMN dose groups plus common training6weeks; ventilatory-threshold measures improved, VO2max and peak power did not. Small sports cohort and selective physiological outcomes; no exact stack, disease outcomes, or general aging benefit.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C29", "text": "108 older adults randomized timing-specific NMN/placebo12weeks; sit-to-stand improved in allgroups and afternoon drowsiness improved with NMN and placebo; interactions reported. Largest within-arm effect does not show universal NMN superiority; multiple groups/endpoints and no exact stack or glycemic disease scope.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C30", "text": "60 older adults randomized NMN250mg/placebo12weeks; primary stepping test null, secondary walking-time/NAD/sleep signals positive. Primary null must accompany secondary positives; ingredient trial cannot establish triple-stack net benefit or extended healthy life expectancy.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C31", "text": "Ten healthy men single-arm acute oralNMN100/250/500mg with metabolites and5hour laboratory measures; no major immediate abnormalities. No randomized comparator or repeated exposure; absence of acute symptoms does not establish long-term safety, clinical efficacy, or stack benefit.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C32", "text": "32 older overweight/obese adults randomized pharmaceutical NMN14days; substantial dose-related NAD rise with short-term tolerability. Biochemical exposure foundation only; no exact stack, durability, or functional disease benefit and no aging-causation proof.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C33", "text": "Mouse berberine improved adiposity/IR while inhibiting gut/liver complexI; fecal transplantation failed to transfer metabolic effect, favoring nonmicrobial explanation in this model. Mouse doses and tissue metabolism do not establish chronic human mediation; transplant negative contradicts obligatory transferable microbiome model, not all microbiome roles.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C34", "text": "Original M/R verify global and beta-cell Kcnh6 knockout abolished acute berberine glucose/insulin effect while tolbutamide remained active;15 healthy men single-dose crossover clamp showed second-phase secretion increase. Animal560mg/kg acute drug dependence plus healthy clamp does not establish endogenous human12week T2D mediation or GLP1 equivalence. Attached34716337 corrects an author-name typo only.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph4, 1:Results:paragraph6, 1:Results:paragraph26, 3:Methods:paragraph1, 3:Methods:paragraph7, 3:Methods:paragraph17, 3:Methods:paragraph18, 3:Methods:paragraph21. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C35", "text": "Acute intralipid insulin resistance improved with berberine; CypD deletion attenuated disease and diminished additional treatment effect; muscle-specific evidence with cells. Acute clamp model and knockout baseline alteration do not isolate all chronic T2D treatment mechanisms or human relevance.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C36", "text": "365 PREMOTE participants secondary meal-test lipid analysis; probiotic plus berberine improved postprandial lipids, with Bbreve/fadD laboratory support. Same parent trial33024120 and different endpoint; not independent glycemic replication, and postprandial lipid synergy is not HbA1c synergy or clinical event reduction.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C37", "text": "Primary mouse hepatocytes showed AMPK/NUR77/FGF21 response; constitutively activeAMPK and compoundC supported pathway involvement. Expression endpoint in isolated cells plus ectopic activation/inhibitor specificity cannot establish endogenous organismal or clinical phenotype dependency.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C38", "text": "High-fat-fed mouse metabolic benefit cooccurred with lower BCAAs and microbiome shifts; ex vivo catabolism and human BCAA/glycemia data included. Covarying pathways and unspecified human treatment design do not show unique microbial/BCAA mediation or satisfy registered clinical trial duration/comparator.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C39", "text": "Mouse/myocyte berberine reduced ectopic muscle lipid and altered mitochondrial function; AMPK/PGC1alpha RNAinterference/adenovirus supported pathway linkage. Lipid/mitochondrial endpoints and experimental constructs do not prove human T2D treatment mechanism or longevity benefits.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C40", "text": "Original Methods/Results:337 diabetes-free obese MASLD participants randomized6months1g/day berberine or matching placebo after tolerance/adherence run-in; VAT,liver fat,bodycomposition and HbA1c effects null despite modest LDL/apoB/CRP reduction. Excludes diabetes and selects tolerant adherers; does not refute T2D glycemic efficacy or establish all-comer safety. Strong boundary against broad adiposity and biomarker-to-weight extrapolation.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph8, 2:Results:paragraph0, 2:Results:paragraph7, 2:Results:paragraph13. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C41", "text": "Sirt3 knockout/overexpression and metabolic assays supported berberine-related mitochondrial/AMP/cAMP/glucose mechanisms and glucagon-pathway inhibition. Multiple downstream routes and model intervention do not isolate human chronic mediation; mitochondrial inhibition is not automatically clinical mitochondrial injury.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C42", "text": "Obese db/db mice berberine increased energy expenditure/BAT and limited weightgain; hypothalamicAMPK genetic activation did not prevent effect. Obesity model thermogenesis does not establish adult clinical weightloss equivalence to GLP1 medicines or necessity of every proposedAMPK site.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C43", "text": "Ovarian KGN cells showed glucose uptake together with SIRT3 ubiquitination, mitochondrial depolarization/complexI inhibition and dose-related ROS/apoptosis signals. Transformed ovarian-cell concentrations cannot demonstrate human T2D efficacy or systemic toxicity; beneficial glucose uptake and adverse cell effects need exposure translation.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C44", "text": "Rat islets berberine inhibited glucose-stimulated secretion/OCR; inhibition disappeared at25mM glucose and compoundC did not reverse OCR effect. Context-dependent secretion conflicts with an unconditional secretagogue narrative; isolated islet result not clinical efficacy falsification or chronic human toxicity.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C45", "text": "184 NAFLD patients randomized open-label lifestyle/pluspioglitazone/plusberberine16weeks; liverfat and weight/IR improved, measured berberine exposure and animal liver studies. Different NAFLD eligibility, common lifestyle and openlabel design; not all participants established T2D or GLP1 comparators; no unique human hepatic mechanism.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C46", "text": "KKAy mice randomized berberine250mg/kg/day or control; glucose/IR/lipids improved with altered skeletal-muscle transcript profile. Transcript changes nominate multiple mechanisms without necessity/rescue; single-species treatment does not qualify chronic human mechanism inference.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C47", "text": "Five-day mouse/in vitro bacterial exposure altered Clostridia/BSH/bile acids and intestinalFXR-associated signals. Short microbial/metabolite perturbation without matched human glycemic dependency; not proven single mediator of clinical benefit.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C48", "text": "Five-week obese-rat treatment improved IR; multiple cell lines increased glycolysis/AMPATP while oxygen consumption declined andAMPK rose. Energy-stress response and cell glucose consumption do not establish human endocrine mechanism; no direct chronicT2D complication endpoint.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C49", "text": "Gut bacteria reduced berberine into more absorbable dihydroberberine; antibiotics lowered conversion/exposure and lipid/glucose effects in KKAy mice. Broad antibiotics alter many processes; absorbed metabolite mechanism and animal doses cannot alone prove human microbiome-specific causal mediation.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C50", "text": "Six-week high-fat-rat treatment improved glucose while lowering insulin; acuteislet/MIN6 berberine inhibited secretion,24hourpretreatment improved response and attenuated glucolipotoxicity. Time/glucose-dependent secretion reversals preclude a universal single-direction secretagogue narrative; culture effects not chronic clinical harm.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C51", "text": "Obese-mouse adipose and isolatedmacrophage inflammation decreased; compoundC/dominant-negativeAMPK abolished cellular anti-inflammatory effects. Cell-specific inhibition and inflammatory markers do not establish clinical T2D mediation, mortality benefit, or exact-stack safety.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C52", "text": "50 hyperlipidemia patients randomized28days dose-ranging BUDCA/placebo; highdoseLDL lowered10.4%, with shorttermPK/tolerability foundation. Not baselineT2D, ordinary berberine,12weeks, or event reduction; no GLP1 equivalence.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C53", "text": "40rats randomized normal/diabetic/drug groups;12week berberine improved glucose/IR and LKB1AMPKTORC2 markers versus diabetic model. No pathway-specific genetic rescue and disease induction/doses differ from humanT2D; protein covariance not necessary mediator.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C54", "text": "Insulin-resistant ratmuscle cells showed enhancedGLUT4/glucose uptake and IRS1/PKC/mTOR-related signaling withberberine. Cellculture metabolic rescue does not establish human chronic clinical causality; multiple route changes not necessity of a single pathway.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C55", "text": "54healthy adults randomized6months oralglutathione/placebo; GSHstores increased, washedout, immune-marker subset signal. Target engagement and antioxidant ratios are not functionalnetbenefit of berberine/GSH/NMN stack or diabetes treatment.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C56", "text": "30overweight older adults randomized28days NMN/placebo; NAD,weight,lipid/diastolic signals improved but insulin sensitivity,physicalperformance and hepatic/intraabdominalfat null. Short small ingredienttrial with many endpoints; no exactstack or durable outcome, and NAD rise not equivalent functional rejuvenation.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C57", "text": "Olderhealthy men randomized6/12weekNMN; NAD rise and nominal gait/leftgrip gains, bodycomposition null. Nominal selective outcomes need replication; no exactstack, T2D clinical endpoint, or agingtrajectory inference.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 57 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C58", "text": "Thirty healthy adults randomizedNMN250mg/placebo12weeks; NAD/NAMN increased, routine physiological/laboratory measures showed no major adverse signal. Bloodtarget engagement and short safety do not establish functional benefit, lifelong safety, or triple-stack efficacy.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 58 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C59", "text": "36healthy middle-aged adults randomized12weekNMN; serum nicotinamide increased but pulsewavevelocity difference nonsignificant. Trend cannot substitute for between-arm arterialfunction benefit; no exactstack or disease events.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 59 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C60", "text": "31healthy adults randomized1250mg/dayNMN/placebo4weeks; no severe adverseevents or out-of-range physiologic changes. Small short-term safety study cannot establish chronic safety or exact-stack netbenefit.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 60 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C61", "text": "60T2D/dyslipidemia samples berberine/placebo metabolomics showed reductions in freefattyacids and treatment-separated profiles. Likely related to2008Zhang diabetes cohort; conservatively grouped until provenindependent. Metabolic covariance not causalmediator or new HbA1c clinicaltrial.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 61 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C62", "text": "2026original built berberine-response proteomic/hormone signature from RCT and linked it to IHD/diabetes via UKBiobank and MR; signalOR.85IHD/.88diabetes. Genetic instrument is a derived signature rather than assigned oralberberine exposure; does not demonstrate clinicalevent treatmentbenefit or GLP1 noninferiority. Cohort/MRcomponents not counted as multiple independentT2D drugtrials.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 62 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C63", "text": "54overweight prediabetic men randomized6groups8weeks HIIT/berberine combinations; exercise benefitedglucose/IR, addingberberine did not addbenefit; berberine-only within-armchanges. Prediabeteslabel with unusuallybroad110–180mg/dL FBG reported and8weeks outside registeredeligibility; within-armchange not treatmentcontrast. No GLP1 headtohead.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 63 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC1", "text": "Exposure and candidate pathway engagement are supported by human PK, the acute healthy-human KCNH6 clamp, PREMOTE microbial/metabolite analyses and causal perturbations in mice and cells. These demonstrate plausible multiple routes, but do not isolate a unique endogenous mechanism for chronic human T2D benefit. Model specificity and biomarker-to-human mediation inferences remain Γ; the actual drug treatment effect is scored separately.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 1, 2, 10, 12, 13, 15, 18, 19, 20, 21, 22, 23, 24, 33, 34, 35, 36, 37, 38, 39, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 61, 62 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC2", "text": "PREMOTE provides a verified twelve-week, concealed, double-blind placebo comparison in drug-naive T2D adults with synthesized berberine 1.2g/day. HbA1c fell by0.99 versus0.59 percentage points; the incremental effect is approximately0.40 percentage points rather than the entire within-arm fall. The older 116-person placebo-controlled three-month trial also supports a glycemic effect. With the explicit clinical-phenotype adaptation, these positive randomized comparisons cross Δ for the registered glycemic-control phenotype. Durable treatment effects across the full range of baseline T2D, products and co-medication have not been mapped. Diabetes-free adiposity nulls do not manufacture an Ε boundary within the registered T2D scope.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 34, 36, 38, 40, 45, 52, 61, 63 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC3", "text": "No examined direct, matched, powered noninferiority comparison establishes berberine equivalence to modern GLP-1 medicines for weight loss or cardiometabolic outcomes. Metformin pilot similarity, short antipsychotic-weight studies and BUDCA biomarker effects are different interventions or contexts. The large six-month diabetes-free obesity trial was null for visceral and liver fat and body composition. Exact class-equivalence claims remain Α, without treating absence of a direct comparison as proof of inferiority on every outcome.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 2, 4, 5, 9, 11, 15, 16, 17, 40, 42, 45, 62, 63 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC4", "text": "No examined trial tests the exact berberine, glutathione and NMN combination with clinical or functional net benefit and component-dismantling controls. Ingredient-specific NAD, glutathione and short functional findings are real but do not establish a triple-stack interaction or long-term safety. Exact stack-benefit claims remain Α; this does not negate separate ingredient effects.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 6, 7, 14, 17, 18, 20, 22, 25, 26, 27, 28, 29, 30, 31, 32, 55, 56, 57, 58, 59, 60 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CH", "text": "Defined berberine can improve short-term T2D glycemic control; modern GLP-1 equivalence, broad weight-loss claims and exact glutathione/NMN stack benefits require separate evidence.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 3, 40, 2, 55 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-13", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "Zhang Y, Gu Y, Ren H et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nature communications. 2020.", "tier": "A", "kind": "rct", "pmid": "33024120", "doi": "10.1038/s41467-020-18414-8", "url": "https://pubmed.ncbi.nlm.nih.gov/33024120/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PREMOTE_NCT02861261", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph0, 1:Results:paragraph9, 1:Results:paragraph17, 1:Results:paragraph18, 3:Methods:paragraph0, 3:Methods:paragraph1, 3:Methods:paragraph2, 3:Methods:paragraph55, 3:Methods:paragraph56, 3:Methods:paragraph76. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC1", "CSC2", "CH" ] }, { "n": 2, "citation": "Ji L, Ma J, Ma Y et al. Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial. JAMA network open. 2025.", "tier": "A", "kind": "rct", "pmid": "40029660", "doi": "10.1001/jamanetworkopen.2024.62185", "url": "https://pubmed.ncbi.nlm.nih.gov/40029660/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "HTD1801_T2D_12week_phaseII", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph3, 1:Methods:paragraph4, 2:Results:paragraph0, 2:Results:paragraph5, 2:Results:paragraph18, 2:Results:paragraph20. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC1", "CSC2", "CSC3", "CH" ] }, { "n": 3, "citation": "Zhang Y, Li X, Zou D et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. The Journal of clinical endocrinology and metabolism. 2008.", "tier": "A", "kind": "rct", "pmid": "18397984", "doi": "10.1210/jc.2007-2404", "url": "https://pubmed.ncbi.nlm.nih.gov/18397984/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Zhang_T2D_dyslipidemia_2008", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC2", "CH" ] }, { "n": 4, "citation": "Panigrahi A, Mohanty S. Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. BMC endocrine disorders. 2023.", "tier": "A", "kind": "rct", "pmid": "37679692", "doi": "10.1186/s12902-023-01442-y", "url": "https://pubmed.ncbi.nlm.nih.gov/37679692/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37679692", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC2", "CSC3" ] }, { "n": 5, "citation": "Harrison SA, Gunn N, Neff GW et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nature communications. 2021.", "tier": "A", "kind": "rct", "pmid": "34535644", "doi": "10.1038/s41467-021-25701-5", "url": "https://pubmed.ncbi.nlm.nih.gov/34535644/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "HTD1801_NCT03656744", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC2", "CSC3" ] }, { "n": 6, "citation": "Mansour A, Sajjadi-Jazi SM, Gerami H et al. The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial. European journal of nutrition. 2025.", "tier": "A", "kind": "rct", "pmid": "39998703", "doi": "10.1007/s00394-025-03618-9", "url": "https://pubmed.ncbi.nlm.nih.gov/39998703/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39998703", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC2", "CSC4" ] }, { "n": 7, "citation": "Nematollahi S, Pishdad GR, Zakerkish M et al. The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial. Diabetology & metabolic syndrome. 2022.", "tier": "A", "kind": "primary", "pmid": "35999562", "doi": "10.1186/s13098-022-00888-9", "url": "https://pubmed.ncbi.nlm.nih.gov/35999562/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35999562", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC2", "CSC4" ] }, { "n": 8, "citation": "Shidfar F, Ebrahimi SS, Hosseini S et al. The Effects of Berberis vulgaris Fruit Extract on Serum Lipoproteins, apoB, apoA-I, Homocysteine, Glycemic Control and Total Antioxidant Capacity in Type 2 Diabetic Patients. Iranian journal of pharmaceutical research : IJPR. 2012.", "tier": "A", "kind": "primary", "pmid": "24250489", "doi": "", "url": "https://pubmed.ncbi.nlm.nih.gov/24250489/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24250489", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC2" ] }, { "n": 9, "citation": "Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental. 2008.", "tier": "A", "kind": "rct", "pmid": "18442638", "doi": "10.1016/j.metabol.2008.01.013", "url": "https://pubmed.ncbi.nlm.nih.gov/18442638/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18442638", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC2", "CSC3" ] }, { "n": 10, "citation": "Nguyen JT, Arian CM, Tanna RS et al. The Pharmacokinetic Interaction Between Metformin and the Natural Product Goldenseal Is Metformin Dose-Dependent: A Three-Arm Crossover Study in Adults With Type 2 Diabetes. Clinical and translational science. 2025.", "tier": "A", "kind": "human_pharmacokinetic_crossover", "pmid": "39943692", "doi": "10.1111/cts.70120", "url": "https://pubmed.ncbi.nlm.nih.gov/39943692/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39943692", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC1", "CSC2" ] }, { "n": 11, "citation": "An Y, Sun Z, Zhang Y et al. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clinical endocrinology. 2014.", "tier": "A", "kind": "rct", "pmid": "23869585", "doi": "10.1111/cen.12294", "url": "https://pubmed.ncbi.nlm.nih.gov/23869585/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23869585", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC2", "CSC3" ] }, { "n": 12, "citation": "Zhang H, Wei J, Xue R et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism: clinical and experimental. 2010.", "tier": "A", "kind": "rct", "pmid": "19800084", "doi": "10.1016/j.metabol.2009.07.029", "url": "https://pubmed.ncbi.nlm.nih.gov/19800084/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19800084", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC1", "CSC2" ] }, { "n": 13, "citation": "Mai J, Zhang H, Wu M et al. Safety and metabolic effects of HTD1801 in type 2 diabetes and MASLD: a phase Ib randomized trial. Diabetology & metabolic syndrome. 2026.", "tier": "A", "kind": "primary", "pmid": "42249406", "doi": "10.1186/s13098-026-02202-3", "url": "https://pubmed.ncbi.nlm.nih.gov/42249406/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "HTD1801_28day_phaseIb", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC1", "CSC2" ] }, { "n": 14, "citation": "Sartore G, Ragazzi E, Antonello G et al. Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial. Nutrients. 2021.", "tier": "A", "kind": "rct", "pmid": "34371883", "doi": "10.3390/nu13072373", "url": "https://pubmed.ncbi.nlm.nih.gov/34371883/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34371883", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC2", "CSC4" ] }, { "n": 15, "citation": "Wei W, Zhao H, Wang A et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. European journal of endocrinology. 2012.", "tier": "A", "kind": "rct", "pmid": "22019891", "doi": "10.1530/EJE-11-0616", "url": "https://pubmed.ncbi.nlm.nih.gov/22019891/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID22019891", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC1", "CSC2", "CSC3" ] }, { "n": 16, "citation": "Qiu Y, Li M, Zhang Y et al. Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin. Asian journal of psychiatry. 2022.", "tier": "A", "kind": "rct", "pmid": "34773803", "doi": "10.1016/j.ajp.2021.102896", "url": "https://pubmed.ncbi.nlm.nih.gov/34773803/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34773803", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC3" ] }, { "n": 17, "citation": "Dahlberg CJ, Ou JJ, Babish JG et al. A 13-week low glycemic load diet and lifestyle modification program combining low glycemic load protein shakes and targeted nutraceuticals improved weight loss and cardio-metabolic risk factors. Canadian journal of physiology and pharmacology. 2017.", "tier": "A", "kind": "rct", "pmid": "28800398", "doi": "10.1139/cjpp-2016-0704", "url": "https://pubmed.ncbi.nlm.nih.gov/28800398/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28800398", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC3", "CSC4" ] }, { "n": 18, "citation": "Wang X, Zhu HJ, Munoz J et al. An ex vivo approach to botanical-drug interactions: a proof of concept study. Journal of ethnopharmacology. 2015.", "tier": "A", "kind": "primary", "pmid": "25623616", "doi": "10.1016/j.jep.2015.01.021", "url": "https://pubmed.ncbi.nlm.nih.gov/25623616/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25623616", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC1", "CSC4" ] }, { "n": 19, "citation": "Liu X, Li W, Zhang H et al. Biodistribution and pharmacokinetic profile of berberine and its metabolites in hepatocytes. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2022.", "tier": "A", "kind": "primary", "pmid": "35785560", "doi": "10.1016/j.phymed.2022.154288", "url": "https://pubmed.ncbi.nlm.nih.gov/35785560/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35785560", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC1" ] }, { "n": 20, "citation": "Xin HW, Wu XC, Li Q et al. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods and findings in experimental and clinical pharmacology. 2006.", "tier": "A", "kind": "primary", "pmid": "16541194", "doi": "10.1358/mf.2006.28.1.962774", "url": "https://pubmed.ncbi.nlm.nih.gov/16541194/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID16541194", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC1", "CSC4" ] }, { "n": 21, "citation": "Alolga RN, Fan Y, Zhang G et al. Pharmacokinetics of a multicomponent herbal preparation in healthy Chinese and African volunteers. Scientific reports. 2015.", "tier": "A", "kind": "primary", "pmid": "26268432", "doi": "10.1038/srep12961", "url": "https://pubmed.ncbi.nlm.nih.gov/26268432/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID26268432", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC1" ] }, { "n": 22, "citation": "Guo Y, Chen Y, Tan ZR et al. Repeated administration of berberine inhibits cytochromes P450 in humans. European journal of clinical pharmacology. 2012.", "tier": "A", "kind": "human_pharmacokinetic_crossover", "pmid": "21870106", "doi": "10.1007/s00228-011-1108-2", "url": "https://pubmed.ncbi.nlm.nih.gov/21870106/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID21870106", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC1", "CSC4" ] }, { "n": 23, "citation": "Zhang X, Qiu F, Jiang J et al. Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein. Xenobiotica; the fate of foreign compounds in biological systems. 2011.", "tier": "A", "kind": "primary", "pmid": "21319959", "doi": "10.3109/00498254.2010.529180", "url": "https://pubmed.ncbi.nlm.nih.gov/21319959/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID21319959", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC1" ] }, { "n": 24, "citation": "Wang Y, Tong Q, Shou JW et al. Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine. Theranostics. 2017.", "tier": "A", "kind": "primary", "pmid": "28744326", "doi": "10.7150/thno.18290", "url": "https://pubmed.ncbi.nlm.nih.gov/28744326/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID28744326", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC1" ] }, { "n": 25, "citation": "Kumar P, Liu C, Suliburk J et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. The journals of gerontology. Series A, Biological sciences and medical sciences. 2023.", "tier": "A", "kind": "rct", "pmid": "35975308", "doi": "10.1093/gerona/glac135", "url": "https://pubmed.ncbi.nlm.nih.gov/35975308/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35975308", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC4" ] }, { "n": 26, "citation": "Yi L, Maier AB, Tao R et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023.", "tier": "A", "kind": "rct", "pmid": "36482258", "doi": "10.1007/s11357-022-00705-1", "url": "https://pubmed.ncbi.nlm.nih.gov/36482258/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36482258", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC4" ] }, { "n": 27, "citation": "Yoshino M, Yoshino J, Kayser BD et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science (New York, N.Y.). 2021.", "tier": "A", "kind": "rct", "pmid": "33888596", "doi": "10.1126/science.abe9985", "url": "https://pubmed.ncbi.nlm.nih.gov/33888596/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33888596", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC4" ] }, { "n": 28, "citation": "Liao B, Zhao Y, Wang D et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Journal of the International Society of Sports Nutrition. 2021.", "tier": "A", "kind": "rct", "pmid": "34238308", "doi": "10.1186/s12970-021-00442-4", "url": "https://pubmed.ncbi.nlm.nih.gov/34238308/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34238308", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC4" ] }, { "n": 29, "citation": "Kim M, Seol J, Sato T et al. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients. 2022.", "tier": "A", "kind": "rct", "pmid": "35215405", "doi": "10.3390/nu14040755", "url": "https://pubmed.ncbi.nlm.nih.gov/35215405/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35215405", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC4" ] }, { "n": 30, "citation": "Morifuji M, Higashi S, Ebihara S et al. Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience. 2024.", "tier": "A", "kind": "rct", "pmid": "38789831", "doi": "10.1007/s11357-024-01204-1", "url": "https://pubmed.ncbi.nlm.nih.gov/38789831/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38789831", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC4" ] }, { "n": 31, "citation": "Irie J, Inagaki E, Fujita M et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine journal. 2020.", "tier": "A", "kind": "primary", "pmid": "31685720", "doi": "10.1507/endocrj.EJ19-0313", "url": "https://pubmed.ncbi.nlm.nih.gov/31685720/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID31685720", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC4" ] }, { "n": 32, "citation": "Pencina KM, Lavu S, Dos Santos M et al. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. The journals of gerontology. Series A, Biological sciences and medical sciences. 2023.", "tier": "A", "kind": "rct", "pmid": "35182418", "doi": "10.1093/gerona/glac049", "url": "https://pubmed.ncbi.nlm.nih.gov/35182418/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MIB626_14day_PK", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC4" ] }, { "n": 33, "citation": "Yu M, Alimujiang M, Hu L et al. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver. International journal of biological sciences. 2021.", "tier": "A", "kind": "primary", "pmid": "33994854", "doi": "10.7150/ijbs.54604", "url": "https://pubmed.ncbi.nlm.nih.gov/33994854/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33994854", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC1" ] }, { "n": 34, "citation": "Zhao MM, Lu J, Li S et al. Berberine is an insulin secretagogue targeting the KCNH6 potassium channel. Nature communications. 2021.", "tier": "A", "kind": "original_model_and_acute_human_trial", "pmid": "34556670", "doi": "10.1038/s41467-021-25952-2", "url": "https://pubmed.ncbi.nlm.nih.gov/34556670/", "status_flags": [ "ErratumIn: PMID34716337" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "KCNH6_models_and_NCT03972215", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph4, 1:Results:paragraph6, 1:Results:paragraph26, 3:Methods:paragraph1, 3:Methods:paragraph7, 3:Methods:paragraph17, 3:Methods:paragraph18, 3:Methods:paragraph21. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC1", "CSC2" ] }, { "n": 35, "citation": "Dong ZH, Lin HY, Chen FL et al. Berberine improves intralipid-induced insulin resistance in murine. Acta pharmacologica Sinica. 2021.", "tier": "A", "kind": "primary", "pmid": "32770172", "doi": "10.1038/s41401-020-0493-4", "url": "https://pubmed.ncbi.nlm.nih.gov/32770172/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32770172", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC1" ] }, { "n": 36, "citation": "Wang S, Ren H, Zhong H et al. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study. Gut microbes. 2022.", "tier": "A", "kind": "secondary_trial_report", "pmid": "34923903", "doi": "10.1080/19490976.2021.2003176", "url": "https://pubmed.ncbi.nlm.nih.gov/34923903/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PREMOTE_NCT02861261", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC1", "CSC2" ] }, { "n": 37, "citation": "Zhou F, Bai M, Zhang Y et al. Berberine-induced activation of AMPK increases hepatic FGF21 expression via NUR77. Biochemical and biophysical research communications. 2018.", "tier": "A", "kind": "primary", "pmid": "29247651", "doi": "10.1016/j.bbrc.2017.12.070", "url": "https://pubmed.ncbi.nlm.nih.gov/29247651/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29247651", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC1" ] }, { "n": 38, "citation": "Yue SJ, Liu J, Wang AT et al. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. American journal of physiology. Endocrinology and metabolism. 2019.", "tier": "A", "kind": "primary", "pmid": "30422704", "doi": "10.1152/ajpendo.00256.2018", "url": "https://pubmed.ncbi.nlm.nih.gov/30422704/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30422704", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC1", "CSC2" ] }, { "n": 39, "citation": "Yao S, Yuan Y, Zhang H et al. Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle. Free radical biology & medicine. 2020.", "tier": "A", "kind": "primary", "pmid": "32745766", "doi": "10.1016/j.freeradbiomed.2020.07.028", "url": "https://pubmed.ncbi.nlm.nih.gov/32745766/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32745766", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC1" ] }, { "n": 40, "citation": "Lei L, Wang B, Zhao L et al. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. JAMA network open. 2026.", "tier": "A", "kind": "rct", "pmid": "41543854", "doi": "10.1001/jamanetworkopen.2025.54152", "url": "https://pubmed.ncbi.nlm.nih.gov/41543854/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41543854", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph8, 2:Results:paragraph0, 2:Results:paragraph7, 2:Results:paragraph13. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC2", "CSC3", "CH" ] }, { "n": 41, "citation": "Zhang B, Pan Y, Xu L et al. Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3. Endocrine. 2018.", "tier": "A", "kind": "primary", "pmid": "30117113", "doi": "10.1007/s12020-018-1689-y", "url": "https://pubmed.ncbi.nlm.nih.gov/30117113/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30117113", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC1" ] }, { "n": 42, "citation": "Zhang Z, Zhang H, Li B et al. Berberine activates thermogenesis in white and brown adipose tissue. Nature communications. 2014.", "tier": "A", "kind": "primary", "pmid": "25423280", "doi": "10.1038/ncomms6493", "url": "https://pubmed.ncbi.nlm.nih.gov/25423280/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID25423280", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC1", "CSC3" ] }, { "n": 43, "citation": "Li W, Li D, Kuang H et al. Berberine increases glucose uptake and intracellular ROS levels by promoting Sirtuin 3 ubiquitination. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2020.", "tier": "A", "kind": "primary", "pmid": "31706105", "doi": "10.1016/j.biopha.2019.109563", "url": "https://pubmed.ncbi.nlm.nih.gov/31706105/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID31706105", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC1" ] }, { "n": 44, "citation": "Bai M, Liu Y, Zhou F et al. Berberine inhibits glucose oxidation and insulin secretion in rat islets. Endocrine journal. 2018.", "tier": "A", "kind": "primary", "pmid": "29467344", "doi": "10.1507/endocrj.EJ17-0543", "url": "https://pubmed.ncbi.nlm.nih.gov/29467344/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29467344", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC1" ] }, { "n": 45, "citation": "Yan HM, Xia MF, Wang Y et al. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PloS one. 2015.", "tier": "A", "kind": "rct", "pmid": "26252777", "doi": "10.1371/journal.pone.0134172", "url": "https://pubmed.ncbi.nlm.nih.gov/26252777/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "NAFLD_NCT00633282", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC1", "CSC2", "CSC3" ] }, { "n": 46, "citation": "Zhang Q, Xiao X, Feng K et al. Berberine Moderates Glucose and Lipid Metabolism through Multipathway Mechanism. Evidence-based complementary and alternative medicine : eCAM. 2011.", "tier": "A", "kind": "primary", "pmid": "20953398", "doi": "10.1155/2011/924851", "url": "https://pubmed.ncbi.nlm.nih.gov/20953398/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20953398", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC1" ] }, { "n": 47, "citation": "Tian Y, Cai J, Gui W et al. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation. Drug metabolism and disposition: the biological fate of chemicals. 2019.", "tier": "A", "kind": "primary", "pmid": "30409838", "doi": "10.1124/dmd.118.083691", "url": "https://pubmed.ncbi.nlm.nih.gov/30409838/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30409838", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC1" ] }, { "n": 48, "citation": "Yin J, Gao Z, Liu D et al. Berberine improves glucose metabolism through induction of glycolysis. American journal of physiology. Endocrinology and metabolism. 2008.", "tier": "A", "kind": "primary", "pmid": "17971514", "doi": "10.1152/ajpendo.00211.2007", "url": "https://pubmed.ncbi.nlm.nih.gov/17971514/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID17971514", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC1" ] }, { "n": 49, "citation": "Feng R, Shou JW, Zhao ZX et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Scientific reports. 2015.", "tier": "A", "kind": "primary", "pmid": "26174047", "doi": "10.1038/srep12155", "url": "https://pubmed.ncbi.nlm.nih.gov/26174047/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID26174047", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC1" ] }, { "n": 50, "citation": "Zhou L, Wang X, Shao L et al. Berberine acutely inhibits insulin secretion from beta-cells through 3',5'-cyclic adenosine 5'-monophosphate signaling pathway. Endocrinology. 2008.", "tier": "A", "kind": "primary", "pmid": "18511510", "doi": "10.1210/en.2007-1752", "url": "https://pubmed.ncbi.nlm.nih.gov/18511510/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID18511510", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC1" ] }, { "n": 51, "citation": "Jeong HW, Hsu KC, Lee JW et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. American journal of physiology. Endocrinology and metabolism. 2009.", "tier": "A", "kind": "primary", "pmid": "19208854", "doi": "10.1152/ajpendo.90599.2008", "url": "https://pubmed.ncbi.nlm.nih.gov/19208854/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19208854", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C51", "CSC1" ] }, { "n": 52, "citation": "Di Bisceglie AM, Watts GF, Lavin P et al. Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. Lipids in health and disease. 2020.", "tier": "A", "kind": "rct", "pmid": "33183320", "doi": "10.1186/s12944-020-01406-4", "url": "https://pubmed.ncbi.nlm.nih.gov/33183320/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "HTD1801_NCT03381287", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C52", "CSC1", "CSC2" ] }, { "n": 53, "citation": "Jiang SJ, Dong H, Li JB et al. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World journal of gastroenterology. 2015.", "tier": "A", "kind": "primary", "pmid": "26167077", "doi": "10.3748/wjg.v21.i25.7777", "url": "https://pubmed.ncbi.nlm.nih.gov/26167077/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID26167077", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C53", "CSC1" ] }, { "n": 54, "citation": "Liu LZ, Cheung SC, Lan LL et al. Berberine modulates insulin signaling transduction in insulin-resistant cells. Molecular and cellular endocrinology. 2010.", "tier": "A", "kind": "primary", "pmid": "20036710", "doi": "10.1016/j.mce.2009.12.027", "url": "https://pubmed.ncbi.nlm.nih.gov/20036710/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID20036710", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C54", "CSC1" ] }, { "n": 55, "citation": "Richie JP, Nichenametla S, Neidig W et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European journal of nutrition. 2015.", "tier": "A", "kind": "rct", "pmid": "24791752", "doi": "10.1007/s00394-014-0706-z", "url": "https://pubmed.ncbi.nlm.nih.gov/24791752/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID24791752", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C55", "CSC4", "CH" ] }, { "n": 56, "citation": "Pencina KM, Valderrabano R, Wipper B et al. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. The Journal of clinical endocrinology and metabolism. 2023.", "tier": "A", "kind": "rct", "pmid": "36740954", "doi": "10.1210/clinem/dgad027", "url": "https://pubmed.ncbi.nlm.nih.gov/36740954/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MIB626_28day_physiology", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C56", "CSC4" ] }, { "n": 57, "citation": "Igarashi M, Nakagawa-Nagahama Y, Miura M et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. npj aging. 2022.", "tier": "A", "kind": "primary", "pmid": "35927255", "doi": "10.1038/s41514-022-00084-z", "url": "https://pubmed.ncbi.nlm.nih.gov/35927255/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35927255", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C57", "CSC4" ] }, { "n": 58, "citation": "Okabe K, Yaku K, Uchida Y et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Frontiers in nutrition. 2022.", "tier": "A", "kind": "primary", "pmid": "35479740", "doi": "10.3389/fnut.2022.868640", "url": "https://pubmed.ncbi.nlm.nih.gov/35479740/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35479740", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C58", "CSC4" ] }, { "n": 59, "citation": "Katayoshi T, Uehata S, Nakashima N et al. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Scientific reports. 2023.", "tier": "A", "kind": "rct", "pmid": "36797393", "doi": "10.1038/s41598-023-29787-3", "url": "https://pubmed.ncbi.nlm.nih.gov/36797393/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36797393", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C59", "CSC4" ] }, { "n": 60, "citation": "Fukamizu Y, Uchida Y, Shigekawa A et al. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Scientific reports. 2022.", "tier": "A", "kind": "rct", "pmid": "36002548", "doi": "10.1038/s41598-022-18272-y", "url": "https://pubmed.ncbi.nlm.nih.gov/36002548/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36002548", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C60", "CSC4" ] }, { "n": 61, "citation": "Gu Y, Zhang Y, Shi X et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta. 2010.", "tier": "A", "kind": "trial_metabolomic_report", "pmid": "20298851", "doi": "10.1016/j.talanta.2010.01.015", "url": "https://pubmed.ncbi.nlm.nih.gov/20298851/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Zhang_T2D_dyslipidemia_2008", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C61", "CSC1", "CSC2" ] }, { "n": 62, "citation": "Zhao JV, Sarsani V, Chen B et al. Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization. NPJ cardiovascular health. 2026.", "tier": "A", "kind": "trial_signature_cohort_and_mendelian_randomization", "pmid": "41882153", "doi": "10.1038/s44325-026-00113-w", "url": "https://pubmed.ncbi.nlm.nih.gov/41882153/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "Berberine_signature_NCT03770325_and_UKBiobank", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C62", "CSC1", "CSC3" ] }, { "n": 63, "citation": "Nikseresht M, Dabidi Roshan V, Nasiri K. Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes. Physiological reports. 2024.", "tier": "A", "kind": "rct", "pmid": "39107107", "doi": "10.14814/phy2.16146", "url": "https://pubmed.ncbi.nlm.nih.gov/39107107/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39107107", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C63", "CSC2", "CSC3" ] } ], "independence_basis": { "required": false, "lines": [], "shared_failure_mode_checked": true, "note": "No model or subclaim reaches Ζ. PREMOTE secondary lipids are one parent; related metabolomics are conservatively grouped; replicate drug trials are not automatically new independently failing modalities. Different model targets do not become additional clinical lines solely by measuring a new molecule. A genuine exact-exposure natural experiment or independently identifying mediator perturbation could exclude distinct systematic errors." }, "gamma_hard_rules_considered": [ { "subclaim_id": "SC1", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Triggered for mouse-to-human mechanism transfer; the human acute clamp establishes secretion physiology but not chronic human T2D mediator dependence." }, { "subclaim_id": "SC1", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Triggered for inferring a necessary clinical mediator from insulin-receptor, BCAA, bile-acid, NAD or inflammatory marker change alone." }, { "subclaim_id": "SC2", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered for directly studied human glycemic-treatment outcomes; animal generalization is not being used to supply this clinical crossing." }, { "subclaim_id": "SC2", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Not triggered for the explicitly registered glycemic-control phenotype itself under the documented clinical adaptation. Triggered for any inference from that phenotype to reduced cardiovascular events, complications, general function or longevity, which are not claimed by the Δ decision." }, { "subclaim_id": "SC3", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Triggered for extrapolating NMN target engagement to clinical benefit; it is not evidence that the exact triple stack was tested." }, { "subclaim_id": "SC4", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Triggered for ingredient-derived clinical/longevity extrapolation from blood NAD or glutathione stores." } ], "supplementary_source_checks": [], "consensus_validation": { "completed": true, "status": "completed_original_source_reconciliation", "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings", "queries": [ "https://consensus.app/search/oral-berberine-glycemic-control/7C9rZ-OjQZqlWCOD1oKQbg/" ], "query_record_note": "Exact provider question/response retained privately in its retrieval receipt.", "primary_comparison_count": 9, "primary_comparisons": [ { "pmid": "33024120", "doi": "10.1038/s41467-020-18414-8", "source_type": "primary study report", "study_group": "PREMOTE_NCT02861261", "access_depth": "full_text_partial", "consensus_aspect": "PREMOTE randomized incremental efficacy and common antibiotic background", "result_comparison": "Consensus accurately identified the common seven-day gentamicin run-in and within-arm HbA1c changes. Original Methods/Results verify concealed double-blind allocation, drug-naive baseline T2D and synthesized1.2g/day berberine for12weeks. The treatment contrast is approximately0.40 percentage points beyond placebo, not the entire0.99-point fall.391 of409 contributed to the primary analysis. Microbial/metabolite associations do not establish uniquely necessary human mediation. The provider's100% meter across11 items is neither a probability that this mechanism is true nor an examined-original count.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/33024120/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\examinations\\original-0-9-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\body-presentation-receipts\\33024120-s1-p0-9-17-18.json", "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\body-presentation-receipts\\33024120-s3-p0-1-2-55-56-76.json" ] }, { "pmid": "34923903", "doi": "10.1080/19490976.2021.2003176", "source_type": "primary study report", "study_group": "PREMOTE_NCT02861261", "access_depth": "abstract_metadata", "consensus_aspect": "PREMOTE secondary lipid report and duplicate-parent control", "result_comparison": "Consensus correctly separated lipid synergy from glycemic superiority. The original abstract explicitly identifies365 participants from PREMOTE, so the report is counted as an original secondary analysis of the same parent trial rather than a new independent glycemic RCT. Its Bifidobacterium/fadD and postprandial lipid findings do not show that probiotics improve HbA1c beyond berberine, and are not cardiovascular event results.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/34923903/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\examinations\\original-27-36-10000.json" ], "body_receipts": [] }, { "pmid": "18442638", "doi": "10.1016/j.metabol.2008.01.013", "source_type": "primary study report", "study_group": "PMID18442638", "access_depth": "abstract_metadata", "consensus_aspect": "Metformin pilot and uncontrolled add-on component", "result_comparison": "Consensus accurately reports36 randomized new-T2D patients and48 add-on patients. The original abstract distinguishes the active-comparator pilot from the uncontrolled add-on study. Similar changes in the pilot do not demonstrate powered noninferiority, and the whole within-arm HbA1c fall cannot be attributed to the drug without a concurrent comparison. Metformin comparison does not establish modern GLP-1 equivalence. The attempted public XML body retrieval failed; this comparison has abstract/status access only.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/18442638/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\examinations\\original-0-9-10000.json" ], "body_receipts": [] }, { "pmid": "40029660", "doi": "10.1001/jamanetworkopen.2024.62185", "source_type": "primary study report", "study_group": "HTD1801_T2D_12week_phaseII", "access_depth": "full_text_partial", "consensus_aspect": "BUDCA formulation and actual dose-specific HbA1c results", "result_comparison": "Consensus correctly names HTD1801 as berberine ursodeoxycholate and reports the high-dose placebo-adjusted0.7-percentage-point HbA1c benefit. Original Methods/Results show113 randomized T2D patients,12weeks and lower-dose0.4-point effect. Weight remained stable. This is a valid distinct-formulation trial, not isolated ordinary-berberine efficacy or evidence of GLP-1-equivalent weight loss. The approximate trial effect does not establish reduced complications.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/40029660/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\examinations\\original-0-9-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\body-presentation-receipts\\40029660-s1-p0-1-3-4.json", "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\body-presentation-receipts\\40029660-s2-p0-5-18-20.json" ] }, { "pmid": "41543854", "doi": "10.1001/jamanetworkopen.2025.54152", "source_type": "primary study report", "study_group": "PMID41543854", "access_depth": "full_text_partial", "consensus_aspect": "Large diabetes-free obesity null omitted from synthesis", "result_comparison": "Despite the question naming the2026 study, the observed Consensus response did not discuss this337-person ordinary-berberine trial and instead used a different multi-ingredient obesity example. Original Methods/Results verify six-month null effects on visceral fat,liver fat,body composition and glycemic measures, with small lipid/CRP changes. Diabetes was excluded, and an active run-in selected tolerant adherers. This omission matters for broad weight-loss and safety narratives; it does not refute the registered baseline-T2D glycemic effect.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/41543854/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\examinations\\original-36-45-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\body-presentation-receipts\\41543854-s1-p0-1-2-3-4-8.json", "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\body-presentation-receipts\\41543854-s2-p0-7-13.json" ] }, { "pmid": "24250489", "doi": "", "source_type": "primary study report", "study_group": "PMID24250489", "access_depth": "abstract_metadata", "consensus_aspect": "Fruit-extract HbA1c null and molecular scope", "result_comparison": "Consensus accurately reports that Berberis fruit extract improved fasting glucose/lipids but not HbA1c. The original31-person three-month trial confirms a between-arm HbA1c null. The exposure was3g/day multicomponent fruit extract, so it is kept as a formulation boundary rather than a pure-berberine T2D null used to erase placebo-controlled drug results.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/24250489/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\examinations\\original-0-9-10000.json" ], "body_receipts": [] }, { "pmid": "37679692", "doi": "10.1186/s12902-023-01442-y", "source_type": "primary study report", "study_group": "PMID37679692", "access_depth": "abstract_metadata", "consensus_aspect": "Prediabetes pilot versus disease prevention", "result_comparison": "Consensus reports normalization of prediabetic markers after84days, matching the34-person pilot abstract. Baseline prediabetes, small sample and branded exposure differ from the registered T2D lead. Moving markers below diagnostic thresholds does not establish prevention of future diabetes, durable remission or complication reduction.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/37679692/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\examinations\\original-0-9-10000.json" ], "body_receipts": [] }, { "pmid": "34556670", "doi": "10.1038/s41467-021-25952-2", "source_type": "primary study report", "study_group": "KCNH6_models_and_NCT03972215", "access_depth": "full_text_partial", "consensus_aspect": "Unresolved chronic mediation and correction status", "result_comparison": "The question requested KCNH6 and its correction, but the observed provider response did not adjudicate them. Original selected Methods/Results verify acute high-dose global/beta-cell mouse knockout dependence and a single-dose clamp in15 healthy men, not chronic human T2D pathway necessity. Attached correction34716337 was actually read and changes only the author-name spelling Tetsuro Izumi. It adds no primary-study count and does not change numerical results.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/34556670/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\examinations\\original-27-36-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\body-presentation-receipts\\34556670-s1-p4-6-26.json", "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\body-presentation-receipts\\34556670-s3-p1-7-17-18-21.json" ] }, { "pmid": "24791752", "doi": "10.1007/s00394-014-0706-z", "source_type": "primary study report", "study_group": "PMID24791752", "access_depth": "abstract_metadata", "consensus_aspect": "Ingredient engagement cannot validate exact triple stack", "result_comparison": "Consensus states that dedicated stack trials are lacking. The original glutathione trial shows increased stores in54 healthy adults after six months, with immune-marker subset results. It tests direct glutathione alone, not berberine/NMN synergy or net clinical benefit. Separate ingredient trials and provider links cannot substitute for an exact combination comparison.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/24791752/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\examinations\\original-54-63-10000.json" ], "body_receipts": [] } ], "grade_changed": false, "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.", "raw_receipts": [ { "path": "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\berberine-glycemic-control\\consensus-browser-2026-10-13.json", "sha256": "4bf857372f3b1dade2b3705b7a168f727cb4504ff768b135a62cb8e1c46dbc2c" } ], "independent_blinded_audit": false, "cutoff": "2026-10-13", "completed_utc": "2026-10-13T17:35:23.262180+00:00", "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them." } }